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Abstract
Translational medicine aims at closing the gap between basic and clinical sciences in an
integrative way. Psychiatry is one of the few medical specialties in which diagnosis is
primarily based on clinical observation and all mental disorders are defined by abnormal
behaviors and cognitions. The lack of biomarkers supporting diagnostic and therapeutic
procedures has been a challenge in psychiatry. A better biological understanding is needed
to move the field forward, it will enhance diagnostics and treatment, while reducing the
stigma that surrounds mental disorders that are so poorly understood.
Over the last years, advances in fundamental sciences like genetics and neuroscience have
made it clear that there is shared biology between many psychiatric disorders and that
integration of methods might lead to new understandings.
The studies presented in this thesis focus on bipolar disorder (BD) and anorexia nervosa
(AN), both severe mental disorders with high suicide rates, high heritability, and both
lacking in biological understanding. BD, formerly known as manic-depressive disorder, is a
mood disorder, characterized by manic or hypomanic episodes, often in combination with
depressive episodes. AN is an eating disorder characterized by severe weight loss together
with pathological behaviors.
This thesis includes five main studies on the biology underlying these disorders, based on
large, well characterized cohorts, covering several methods, including genetic, imaging and
protein markers, as well as preliminary data on the establishment of in vitro models.
Specifically, in study I, we attempted to replicate previously published findings on the
association between subphenotypes of bipolar disorder and genetic variations in the AKT1
gene. Using frequentist and Bayesian approaches, as well as publicly available results
from genome-wide association studies (GWAS), we were able to reject previously proposed
associations.
In study II, we explored the effects of genetic variations in genes involved in glutamate
regulation on glutamate levels in two brain regions and their associations with other
phenotypes. We found that the minor allele of rs3812778/rs3829280 in the 5’-untranslated
region of SLC1A2, coding for a glutamate transporter, is associated (1) with increased
glutamate levels in the anterior cingulate cortex, (2) with increased expression levels, in
several brain regions, of the transmembrane receptor gene CD44, which is implicated in
inflammation and brain development, as well as (3) with an increased risk for rapid-cycling
in bipolar disorder, potentially linking CD44/SLC1A2 to a more severe phenotype of BD.
In study III, we investigated the effects of clinical and genetic parameters on lithium
pharmacokinetics in order to better understand lithium biology and improve lithium dose
prediction models for bipolar patients, using the ratio between serum lithium and daily
lithium intake, as outcome. We were able to confirm the association of several clinical
predictors. Although no genome-wide significant locus was found, we report that genetic
variation is important and might influence the outcome. Finally, based on the results
obtained in the study, we developed a prediction algorithm that can be tested in the clinic.
In study IV, we investigated the involvement of neuronal degeneration in AN by studying
neurofilament light chain (NfL), a known marker of neurodegeneration, in a case-control
setting and found increased levels of NfL in patients with active AN in two different cohorts.
In study V, we studied the involvement of inflammation in AN, using a panel of 92
inflammatory markers in a case-control setting and report an aberrant inflammatory profile
in patients with active AN, but not in patients that have recovered from AN.
These studies exemplify possible approaches that can be taken in translational psychiatry.
The integration of clinical, technical and analytical approaches illustrates important
learning outcomes for an aspiring clinical scientist in psychiatry.
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Chapter 1
Introduction
1.1 Translational Psychiatry
1.1.1 “A bridge to somewhere”?
Translational medicine is the research area that aims at closing the gap that exists between
basic and clinical sciences, in an integrative way. While clinical questions can become
scientific hypotheses, novel biological results can be adapted to be used in clinics. This
method, often referred to as bench-to-bedside or bed-to-bench-to-bedside, has been widely
successful in somatic medicine.
Psychiatry is one of the few medical specialties in which diagnosis is primarily based
on clinical observation, as all mental disorders are defined by abnormal behaviors and
cognitions. This sets it apart from other specialties that are able to rely on lab tests,
imaging methods and other more objective measurements that allow for a more precise
diagnostic. The lack of biomarkers supporting diagnostic and therapeutic procedures
has been a challenge in psychiatry. A better biological understanding is needed to move
psychiatry forward, it will enhance diagnostics and treatment, while reducing the stigma
that surrounds mental disorders that are so poorly understood.
Over the last years, major advances have been made, both in neuroscience and genetics.
Although they have not yet been translated into direct clinical application in psychiatry,
they have led to a better understanding of some of the biology. It has become clear that
there is shared biology between many psychiatric disorders1 and that overcoming classical
definitions and analyzing disorders together can lead to new insights2,3. These studies have
also provided examples of improved research methodology. The integration of cohorts and
methods in big international consortia have led to robust and reproducible results and
made it possible to capture the complexity of the disorders and analyze gene-environment
interaction in new ways4.
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However big the gap, it appears that a bridge is currently being built. Nine years ago,
Tomas Insel wrote a guest editorial about translational psychiatry entitled “A bridge to
somewhere”5. In a way, this is the feeling I personally have as an early career scientist.
Facing the complexity of these disorders and the current advances made, it feels like being
a small worker on a huge bridge building project. The other end might not be in sight yet,
but it feels that the direction is right.
In this thesis, I have used several approaches, worked on different methods and disorders,
focusing on bipolar disorder and anorexia nervosa. Although this was not the plan from
the beginning, I ended up participating in the building of not one but several bridges. I
hope it ends up as an asset.
1.1.2 Diagnostic criteria in psychiatry
Diagnosis of psychiatric disorders is based on clinical observation and the description
of symptoms. Two major diagnostic manuals are used by clinicians for the diagnosis
of psychiatric disorders, chapter F in the International Classification of Diseases (ICD)
published by the World Health Organization (WHO), currently in its tenth edition6,
and the Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the
American Psychiatric Association, currently in its fifth edition7. The introduction of these
manuals has had a big influence in harmonizing psychiatric diagnoses all around the globe,
leading to an increased reliability of diagnoses. The DSM is the main manual used by
clinicians in the USA, as well as by many researchers internationally. It has however been
criticized for its lack of validity, as diagnosis is mainly based on symptomatology and not,
as in many other medical specialties, on more objective biological measures8. The authors
of the DSM are aware of these shortcomings, but argue in the introduction that “past
science was not mature enough to yield fully validated diagnoses” and “speculative results
do not belong in an official nosology”7. The splitting up of the section on affective disorders
into a section on major depressive disorder (MDD) and one on bipolar disorder (BD) is
however, partially, based on biological findings, as the section on BDs is placed between
the sections on Psychotic Disorders and Depressive Disorders “in recognition of their place
as a bridge between the two diagnostic classes in terms of symptomatology, family history
and genetics”.7
These classifications are primarily designed for clinical use and disease categories are not
as homogenous as in other medical fields. The National Institute of Mental Health has
therefore developed the Research Domain Criteria (RDoC) to find new ways of studying
mental disorders, developed around psychological constructs, which can be analyzed at
different levels of information, going from genes to behavior9.
Another approach is to decompose psychiatric diagnoses into endophenotypes to reduce
the heterogeneity. These are defined as a set of “neurophysiological, biochemical,
endocrinological, neuroanatomical, cognitive or neuropsychological” features that would
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allow more homogeneous grouping and facilitate genetic and biological understanding of
psychiatric disorder10. This is the approach we have chosen in several of our studies,
including the analysis of endophenotypes (e.g. psychosis, rapid cycling, lithium response)
to create more homogenous groups.
1.1.3 Biomarkers in psychiatry
Currently, the use of biomarkers in confirming diagnoses of psychiatric disorders is limited
and laboratory tests are mostly used to exclude organic causes of a disorder. However, it is
widely understood that objective measurements and in particular biomarkers are needed to
address the problem of heterogeneity in psychiatric disorders. Biomarkers are “objectively
measured and evaluated indicators of normal biological processes, pathogenic processes or
pharmacologic response to therapeutic intervention”11. Biomarkers can therefore be of
several types, e.g. diagnostic, predictive, prognostic12. Development of biomarkers is tightly
linked with a better understanding of the biology of psychiatric disorders, and advances in
both fields will most probably go hand in hand.
1.1.3.1 Genetics in psychiatry
Many psychiatric disorders have a high heritability, and genetic studies have been
quintessential in driving the understanding of psychiatric disorders forward over the last
25 years. Initially, so-called linkage studies focused on a few large families to identify rare
gene variants conferring a high degree of disease risk. With increasing knowledge of the
human genome and the common genetic variability, and the technological possibilities
to easily genotype bigger cohorts, the focus was shifted to association studies. These
are based on the correlation between disease status and genetic variation in cases versus
unrelated controls and research using this approach has been extremely prolific. This
method has however been criticized, as results can often not be replicated13,14, and most
results cannot be confirmed by meta-analyses. Furthermore, candidate genes are often
used, with a selection based on our current understanding of the disorders. The method
is therefore inherently biased towards well-studied pathways.
The current state of the art method in genetics are genome-wide association studies
(GWAS) (cf. 3.2.3). When sufficiently powered, GWAS yield robust and replicable results
that can often even enable valid predictions in new datasets. This is particularly true in
psychiatry, where the efforts of the Psychiatric Genomics Consortium (PGC) have not only
fundamentally changed our understanding of psychiatric genetics, but in several ways even
brought forward new understanding of pathological mechanisms underlying psychiatric
disorders15. Furthermore, even if early GWAS studies, based on small samples, often do
not find statistically significant results, it is well established that above a certain threshold,
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the number of hits is linearly associated with the number of patients15 and collecting bigger
sample sizes will lead to findings, as long as the trait is partially heritable.
GWAS have today brought up genetic associations for all main psychiatric disorders,
leading to a better understanding of their biology. Furthermore, polygenic risk scores
(PRS) that summarize the effect sizes of multiple genetic loci have been shown to predict
phenotypes in independent cohorts. Even if their explanatory power is at the moment very
low, these PRS represent a possible new way stratifying patients according to risk.
1.1.3.2 Imaging biomarkers
The brain as the obvious organ affected in psychiatric disorders has been another main
research target. Diverse imaging methods have been used to study different aspects of
the disorders, including magnetic resonance imaging (MRI) to study structural variation,
functional MRI (fMRI) to study brain activity, magnetic resonance spectroscopy (MRS)
to study metabolite concentrations, diffusion tensor imaging (DTI) to study white
matter connectivity and positron emission tomography (PET) to study several biological
processes16. For a long time, studies were single-centered, included relatively few
individuals and results were often inconsistent. Therefore, despite the ever-increasing
number of studies, few results have been translated into clinical practice and imaging is
mainly used in the diagnosis of neurocognitive disorders, like dementias16.
However, in recent years, the creation of large consortia has led to more reliable results, in
a similar fashion than genetics. In particular, the ENIGMA consortium (Enhancing Neuro
Imaging Genetics by Meta-Analysis) has driven the imaging field forwards, performing
multi-center mega-analyses with unified protocols that include data from thousands of
patients. Working groups exist for all major psychiatric disorders. Several imaging methods
have been integrated, as well as genetic data, that allows GWAS to be performed. While
the MRI field is already driven by the ENIGMA consortium, other fields (e.g. PET, MRS)
have yet to produce mega-analyses based on collaborative research17.
1.1.3.3 Blood biomarkers
Markers that can be measured in peripheral blood would be among the easiest to
establish in clinical practice, as they could be combined with routine testing. Although
a plethora of associations has been found for almost all psychiatric disorders, no blood
marker has so far been established as a clinical biomarker. This can partly be explained
by methodological problems, the aforementioned heterogeneity, a lack of specificity
(e.g. low-grade inflammation present in diverse conditions18), as well as the complexity
of the disorders that might require combinations instead of single markers (cf. Teixeira
et al.19 for BD). However, the continuous research using new methodologies (cf. ‘omics’)
might end up producing biomarkers that would allow us to differentiate and stratify
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patient groups. For example, the effect of anti-inflammatory agents seen in the treatment
of MDD might be enhanced if focusing only on patients presenting with increased levels
of inflammation20.
1.1.3.4 Cell models in psychiatry
To establish biomarkers, a better understanding of the biology is often necessary. Although
animal models have been very important in understanding conserved neuronal molecular
pathways, no rodent model fully recapitulates any psychiatric disorder defined in DSM-V.
The same applies to commonly used immortalized cell lines as in vitro models, as they
also fail to capture the full genetic complexity of psychiatric disorders. To understand the
underlying molecular bases, the use of patient tissue is therefore of utmost importance.
For a long time, the only way to get patient tissue was to sample peripheral tissue (e.g. skin
fibroblasts or leukocytes), or to take post-mortem brain biopsies. Both approaches capture
the genetic background, but have intrinsic limitations. Peripheral tissue can play a role in
the pathophysiology of psychiatric disorders, however the most striking differences are
to be expected in the cells of the central nervous system (CNS). Post-mortem brain
biopsies provide insight in the pathophysiological processes taking place in the CNS but
typically show the end stage of the disorder, often confounded by life-long therapies and/or
comorbidities21.
With the advent of induced pluripotent stem cells (iPSCs), many of these challenges can be
solved. As iPSCs can be derived from practically any peripheral cell, including fibroblasts22
and peripheral blood23, tissue collection only poses minor ethical problems. iPSCs can be
differentiated into any cell type and protocols for neural differentiation are becoming more
and more precise. It is thus now possible to obtain neurons with the genetic background
of psychiatric patients. In disorders with a high heritability, these models could lead to a
better understanding of the underlying pathophysiological processes and in consequence,
the development of biomarkers.
In psychiatry, the first results involving iPSC were published for schizophrenia, where
patient derived neurons showed decreased connectivity, synapses, spine density and
expression of glutamate receptors24. In BD, patient derived neurons were shown to
be hyperexcitable when compared to neurons from healthy controls. This phenotype
was reversed by lithium treatment in neurons from lithium responders but not from
non-responders25,26.
Although several promising results have been published on iPSC models of psychiatric
disorders, it is probable that many of the studies are currently underpowered and results
might not replicate. Indeed, as has been shown by the advances in psychiatric genomics,
there is important heterogeneity in psychiatric cohorts that can hardly be captured
by current sample sizes. Also, intra-donor variation (i.e. between two iPSC lines from
the same donor) is higher than often expected. Several possible ways have therefore
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been suggested to overcome this problem27: (1) Heavily increasing the number of
included patients. However, based on adequate power for post-mortem studies that has
recently been estimated to be above 25,000 patients28, this is a challenging task that
will require collaborative effort29; (2) reducing inter-patient heterogeneity, by focusing
on well-characterized subphenotypes or on carriers of rare variants; (3) studying single
mutations using CRISPR-based tools.
1.2 Bipolar Disorder
1.2.1 Clinical presentation
Bipolar disorders (BD), formerly known as manic-depressive disorders, are characterized
by manic or hypomanic episodes, and depressive episodes. Manic episodes are defined
as periods of abnormally elevated mood, with patients being euphoric, excessively
cheerful, and full of energy, sometimes described as feeling on top of the world. Further
characteristics are a reduced need for sleep, increased self-esteem, flight of ideas, often in
combination with risky behaviors. Depressive episodes are defined by a depressive mood,
diminished interest in activities, sleep disturbances, loss of energy, low self-esteem30.
Psychotic episodes can accompany both manic and depressive episodes, even though they
are more common during mania31.
Although the current diagnostic criteria as defined in DSM-V and ICD-10 are similar, small
differences exist. In the DSM-V for example, a distinction between BD type 1 and BD type
2 can be found. A single life-time manic episode1 is sufficient for a BD type 1 diagnosis,
while a diagnosis of BD type 2 requires a hypomanic2, as well as a depressive episode.
The DSM also defines several specifiers, with anxious distress, with mixed features, with
melancholic features, with atypical features, with psychotic features, with peripartum onset,
with seasonal patterns. BD patients with rapid cycling are individuals who have multiple
(four or more) mood episodes within one year. BD patients with psychotic features can
be defined according to mood congruency, that is, whether the content of the psychosis
is in accordance with mood polarity. While the main criteria for diagnosing BD have not
changed significantly between the DSM-IV and the DSM-V, the typing according to the
latest episode in BD type 1 has been removed in DSM-V32.
The ICD-10 defines hypomania (F30.0), mania without psychotic symptoms (F30.1), mania
with psychotic symptoms (F30.2), but only a single bipolar diagnosis (F31), which is
however subdefined according to the current affective state and the presence or absence of
psychosis.
The precise diagnostic criteria defined by the DSM or ICD can be found in appendix A.1.
1A manic episode entails marked impairment in functioning and lasts at least one week.
2A hypomanic episode is less severe, (no severe impairment) and shorter (4 days or more).
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1.2.2 Epidemiology
One of the most extensive epidemiological data sets regarding bipolar spectrum disorders
comes from the WHO World Mental Health study, which includes data from over 60,000
individuals from 11 countries33. The study reports an average 12-month prevalence of
approximately 0.4% for BD type 1 and 0.3% for BD type 2. The lifetime prevalence
is 0.6% and 0.4%, respectively. The authors also study subthreshold BD, defined as the
presence of at least one symptom on the screening questions for mania, but not meeting
the criteria for hypomania. This form of BD has 0.8% and 1.4% 12-month and lifetime
prevalence, respectively. When pooling all three forms, the USA has the highest 12-month
and lifetime prevalence (2.8% and 4.4% respectively), India the lowest (0.1% and 0.1%).
The mean age of onset is 18.4 for BD type 1, 20.0 for BD type 2 and 21.9 for subthreshold
BD. These results are in concordance with several previous studies34. BD type 1 is more
frequent in men, while BD type 2 is more common in women, however overall, sex does
not seem to be a major risk factor34.
About one third of patients with a lifetime history of BD experience rapid-cycling35. Rapid
cycling can be considered a more severe form of BD, as patients do not only have many
more episodes, but also a younger age of onset, higher persistence, more severe depressive
episodes35. Up to two-thirds of patients with BD are estimated to have at least one episode
of psychosis during their lifetime36.
Seventy-five percent of all patients with one form of BD have at least one psychiatric
comorbidity, but many patients have three or more disorders. Anxiety disorders (62.9%),
behavioural disorders (44.8%) and substance use disorders (36.6%) are the most common
comorbidities33. Another important problem among BD patients is suicidality with 43.4%
reporting suicidal ideation, 21% planning, and 16% making suicide attempts over the last
year. A recent meta-analysis reports 0.164 suicides per 100 person-years37, meaning that
approximately 3.4-5.9% of all suicide deaths occur among people with BD.
1.2.3 Pathophysiological considerations
As discussed in section 1.1.2, BD is a clinical diagnosis, currently not based on any
(neuro)biological definition. This is partly due to the fact that the pathophysiology of
BD is still poorly understood and no clinically useful biomarkers exist. Unfortunately,
this creates a vicious circle, as the purely descriptive definition most probably pools
conditions together that, although having the same clinical presentation, represent different
pathological entities38, which in turn makes the discovery of neurobiological substrates
more difficult. Nevertheless, the last years have seen advances in the understanding of
the disease, mainly driven by large consortia, which give hope that better definitions are
possible. In this section, I will discuss the most established findings, focusing in particular
on pathophysiological aspects important for the studies included in the thesis.
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1.2.3.1 Genetics
BD runs in families and many patients have relatives with a history of mood or psychotic
illnesses. Family history of the disorder is therefore used by clinicians to strengthen a
new diagnosis.3 Twin studies have revealed a heritability of 60-80% and a monozygotic
concordance rate of 40-70%39,40. The relative risk for a sibling of a patient compared to risk
in the general population is about eight-fold39,40. These estimates are among the highest
for any psychiatric disorders31. In general, studies suggest that, like most psychiatric
disorders, BD is characterized by polygenic inheritance, based on many common variants
with small effect sizes38, increasing the risk in interaction with environmental factors31.
There is important genetic overlap with other psychiatric disorders, including schizophrenia
(r=0.7), MDD (r=0.36), and obsessive-compulsive disorder (OCD) (r=0.31)41. Finally,
there seems to be a positive genetic correlation between BD and AN (r=0.19-0.21)41,42, even
though, in the latest analysis, its p-value (p = 2 · 10−4) was just above the predetermined
significance level (α = 1 · 10−4)42.
Many gene association studies have been performed before the GWAS era, focusing mainly
on biologically plausible candidates like the serotonin transporter gene SERT, the brain
derived neurotrophic factor gene BDNF and the catechol-o-methyl transferase gene COMT.
Many hundreds of SNPs have been associated to BD, however, robustness of these findings
is an issue, as can be exemplified by a meta-analysis which included 33 SNPs43. In this
study, only SNPs in four genes (BDNF, the dopamine receptor D4 gene DRD4, the D-amino
acid oxidase activator gene DAOA, and the tryptophan hydroxylase gene TPH1 were found
to be significant at a significance threshold of α = 0.05 and none of the results remained
statistically significant after correcting for multiple testing. This is further exemplified in
study I of this thesis (cf. 4.1, where using a large sample, as well as public GWAS data,
we propose that published associations between variants in AKT1 and BD are less likely
to be true.
The advent of large GWAS, driven by the PGC, has led to a major change in the
understanding of the genetics of BD and growing patient cohorts included in the studies
have brought forward robust and reproducible results. The latest published GWAS44 is a
meta-analysis of 32 cohorts from 14 countries, including a total of 20,352 cases and 31,358
control, testing for almost 10,000,000 autosomal variants with a minor allele frequency
(MAF) > 1%. All variants with p < 10-4 were then tested for association in an independent
follow-up sample. This study reports 30 loci that achieved genome-wide significance, in
the combined sample: these are located among others near genes involved in calcium
signaling (CACNA1C, encoding for L-type calcium channel subunit gene), genes involved
in ion transport (SCN2A, encoding for a sodium voltage-gated channel subunit; SLC4A1
encoding an anion exchanger; ANK3, encoding ankyrin 3, involved in the localization
of sodium channels), glutamate signaling (GRIN2A, encoding for a NMDA-receptor
3Personal communication from Dr. Lena Backlund
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subunit), as well as other genes involved in brain physiology (NCAN, encoding the brain
expressed extracellular matrix glycoprotein neurocan that is involved in neuronal adhesion
and neurite growth45). Pathway analyses pointed towards an involvement of insulin and
endocannaboid signaling44.
The overlap between BD and schizophrenia is also supported by the fact that many of the
reported loci have previously been associated with schizophrenia (e.g. TRANK1, ITIH1,
CACNA1C, NCAN )46. Furthermore, a combined analysis of BD and schizophrenia revealed
over a hundred loci associated with the combination of both disorders, many of them related
to synaptic and neuronal biology2. In this analysis, only 2 loci were divergent between BD
and schizophrenia. Interestingly, the PRS based on the BD cohort was able to predict
psychosis in BD, while a BD PRS was associated with manic symptoms in schizophrenia.
Copy-number variants (CNV) have also been implicated in BD. Although being less
common, they yield a far bigger effect size than common SNPs. A meta-analysis
performed by Green and colleagues found three CNV loci (1q21.1 duplication, 3q29
deletion, 16p11.2 duplication) with odds ratios of 2.6-17.347. These CNV are also
associated with schizophrenia48. Overall CNV involvement in BD is less important than
in schizophrenia49.
1.2.3.2 Imaging
The Bipolar working group of the ENIGMA consortium has published several MRI studies
providing evidence for changes in cortical and subcortical grey matter, as well as in white
matter connectivity. Cortical grey matter was shown to be thinner in frontal, temporal and
parietal regions of BD patients compared to healthy controls50. Furthermore, BD patients
had a reduced volume of the hippocampus and thalamus, enlarged ventricles51, as well
as lower fractional anisotropy, a measure of neural connectivity, in several white matter
tracts, with the biggest effects seen in the corpus callosum52.
As mentioned in 1.1.3.2, other imaging techniques (e.g. PET, MRS) have not formed
big consortia and the results of these methods are therefore best summarized through
(systematic) reviews and, where possible, meta-analyses. One such result is the
glutamatergic dysregulation shown in BD patients using MRS (cf. 3.3). A meta-analysis
including 17 studies comparing BD patients and healthy controls reported higher levels
of Glx (glutamate + glutamine) in the frontal areas and when combining all regions.
Furthermore, it also found non-significant trends for increased Glx/Creatine ratio and
glutamate when combining all regions53. A separate meta-analysis including 15 studies on
frontal regions and eight studies on the anterior cingulate cortex (ACC) concluded that
BD patients showed significantly elevated Glx levels in both regions54.
There has been some effort to integrate genetic and imaging studies in order to achieve a
better understanding of the biology behind BD, among others by the ENIGMA consortium.
Several smaller studies, mainly based on candidate genes, have brought forward results,
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but only few have been replicated. GWAS with imaging data has so far not revealed any
genome-wide association for imaging findings in BD. A recent systematic review55 however
highlights several associations supported by more evidence, including (1) the association
between genetic variation in CACNA1C and activation of the amygdala; (2) the association
between genetic variations in ANK3 and white matter structure; (3) the association
between the BDNF met allele in rs6265 and smaller hippocampal volumes. However, due
to several methodological limitations (e.g. sample size, correction for mood states) these
results have to be interpreted with care.
1.2.3.3 Cell culture
As discussed in 1.1.3.4, in vitro disease modelling is a powerful tool that combines the
advantages of harbouring the genetic information of patients with the possibility of
mechanistically testing for effects of drug treatment or altering genes of interest. Over the
years, BD has been very extensively modelled using peripheral models like lymphoblastoid
cell lines and fibroblasts. These studies highlighted changes in several intracellular signaling
mechanisms (e.g. calcium signaling, inositol signaling), as well as in mitochondria, oxidative
stress and circadian rhythm56. More recently, several iPSC-based studies have provided
new insights into potential disease mechanisms: Neurons differentiated from iPSC derived
from BD patients were shown to be hyperexcitable, a phenotype, which can be reversed
by lithium treatment25. Furthermore, electrophysiological characteristics were found to
differentiate between lithium responders and non-responders26. Finally, similarly to other
psychiatric disorders iPSC-based models have been proven to be interesting to follow-up
on GWAS results in BD. For example, a recent study showed that iPSC derived neural
progenitor cells carrying the risk allele for BD of rs9834970 near the TRANK1 gene,
had lower baseline TRANK1 expression and that this phenotype could be rescued by
treatment with valproate57.
1.2.3.4 Further pathophysiological considerations
Neuropathological changes. While there has been many studies on neuropathological
changes in BD, most of them rely on small samples, and few results have been replicated. A
recent meta-analysis found support for some findings, including decreased cortical thickness
in the ACC and reduced neuronal density in the amygdala, while pointing out that no
pathological finding can be considered to be established “beyond reasonable doubt”58.
Neuroendocrinology. The involvement of the hypothalamic–pituitary–adrenal (HPA)
axis has for a long time been well established59. A recent meta-analysis showed that
BD patients have higher cortisol (awakening, morning, afternoon, night) and basal
adrenocorticotropic hormone levels, but found no difference in corticotropin releasing
hormone60. Furthermore, euthymic BD patients show a flattening of the cortisol curve,
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which indicates a HPA axis dysregulation61. BD patients also exhibit higher levels of
extra-neuronal noradrenaline62, as well as disturbed thyroid function63.
Inflammation. Increased inflammation is well documented in BD. Several cytokines and
their receptors have been shown to be elevated in BD, depending on the mood state,
by several meta-analyses including C-reactive protein (CRP), Interleukin (IL) receptor 1
antagonist, IL6, soluble IL-2 receptor (sIL-2R), sIL-6R, tumor necrosis factor (TNF)-α,
soluble TNF receptor type 164–66. Furthermore, BD has positive genetic correlations with
several immune-related conditions, including celiac disorder, psoriasis, ulcerative colitis,
and Crohn’s disease67.
Circadian dysfunction. Circadian disturbances have been strongly associated with BD
in all three states of the disorder (mania, depression and euthymia). Changes in many
characteristics of sleep quality68–70, delayed and irregular sleep-wake cycles71 and abnormal
daily activity72 have been reported. These clinical characteristics are in congruence with
reported disturbances in melatonin signaling68,69,73.
Mitochondrial function. Disturbances in mitochondrial function and energy
dysregulation have also been linked to BD74. This has been characterized among
others by increased reactive oxygen species production and decreased mitochondrial
complex subunits in the brain.
1.2.4 Treatment
1.2.4.1 General considerations
Although BD cannot be cured today, it is highly treatable and manageable. Treatment
is based on so called mood stabilizers, which include lithium, anticonvulsants and some
atypical antipsychotics, and up to 90% of patients achieve a substantial improvement
of their condition. Unfortunately, many patients are not receiving adequate treatment,
particularly in low income countries, only a minority of patients have contact with the
mental health system33.
1.2.4.2 Lithium
The alkali metal lithium was first used in 1949 to treat “psychotic excitement”75 and has
since then been established as the cheapest and most effective treatment for BD76. It is
often prescribed for life and leads to a substantial increase in life quality. Lithium has a
very small therapeutic window (0.5-1.3 mEq/L), with lower levels generally considered
subtherapeutic and higher levels being toxic. Toxic effects include gastro-intestinal
symptoms, drowsiness, tremor, muscle weakness at levels above 1.5 mmol/L; levels higher
than 2 mmol/L can be severely toxic, leading to seizures, kidney failure, hyperthermia,
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coma and delirium, and require intensive care77. Lithium has excellent anti-manic and
anti-suicidal effects78. Its effects on depression are however less potent. Approximately
one third of the patients responds extremely well to lithium, while one third does not
respond at all79.
1.2.4.2.1 Pharmacodynamics
The exact mechanisms of lithium are currently unknown, but many biological pathways
have been suggested to play a role. On a cellular level, lithium mediates neuroprotection
through inhibition of glycogen synthase kinase 3β (GSK-3β), the increase of peripheral
BDNF levels and influencing oxidative metabolism and apoptosis80,81. It further influences
several second messenger systems, including the phosphoinositide cycle, with lithium
treatment leading to increases in myo-inositol levels, protein kinase C, intracellular
calcium, and adenyl cyclase80,81. Lithium also acts on neurotransmission, including
glutamate, dopamine and γ-aminobutyric acid (GABA) signaling. Finally, it influences
higher order biological systems like circadian rhythm, the HPA axis, as well as the repair of
gray and white matter abnormalities80,81. However, although many different mechanisms
have been suggested, it is unlikely that any single one of them can explain the anti-manic
and anti-suicidal effects of lithium alone. For example, a study comparing lithium to
selective GSK-3β inhibitors in rats concluded that even if some effects could be seen with
both components, the overall effects were fairly different82.
1.2.4.2.2 Pharmacokinetics
Lithium is most commonly administered as tablets. Different lithium salts exist,
e.g. carbonate, acetate, citrate, gluconate and sulfate, all have however a bioavailability of
80-100%83. After uptake in the proximal parts of the small intestine84, lithium enters the
blood stream as free ions. Contrary to many other drugs, lithium is not metabolized and
distributes freely in the body, according to a two-compartment model83,85. Brain lithium
concentrations are generally considered to be smaller than serum concentrations86, with
important heterogeneity within the brain87.
Lithium is primarily eliminated through the kidneys83: It is filtered in the glomeruli,
however, 70-80% are reabsorbed in the proximal tubules together with sodium ions88, which
can lead to increased lithium reabsorption and higher serum levels during hyponatremia83.
The terminal elimination half-life is estimated at 20-40 h89,90. Several variables have
been found to influence elimination and explain part of the variability, e.g. age91, kidney
function89, body mass index (BMI)92 and treatment duration93. Disorders of the kidney
and the heart, as well as co-medication with sodium-depleting diuretics, antihypertensive
agents and non-steroidal anti-inflammatory drugs (NSAID) have been shown to reduce
lithium elimination85.
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1.2.4.2.3 Pharmacogenomics
Even if some clinical features (initial good response, positive family history of BD with a
good response to lithium, BD type 1) can be used to help to predict lithium response, no
generally accepted biological marker exists94. There is evidence that lithium response
is a heritable trait, which has led to several pharmacogenomic studies trying to find
genetic markers associated with lithium response. The biggest study so far, published
by the International Consortium on Lithium Genetics (ConLiGen), found a single locus on
chromosome 21, containing two genes for long, non-coding RNAs, associated with lithium
response. The collection for a new GWAS is currently ongoing.
1.2.4.2.4 Treatment regimen
Because of its small therapeutic window, lithium dose has to be adjusted to each patient,
to avoid toxic effects. Usually, lithium therapy is started by an individual titration. A low
dose is given (in Sweden usually 2 tablets of lithium sulfate, i.e. 12 mmol/day) and the
serum concentration is measured when the steady state is reached after approximately one
week. The dose can then be adapted, and the process is repeated until the planned levels are
reached95. The finally required dose can vary greatly. During the initiation period, which
can take several weeks, the patients are not adequately treated. Unfortunately, there is no
model to predict the amount a patient has to take to reach therapeutic levels. However,
even if the clinical variables influencing lithium pharmacokinetics are well studied, they
only explain part of the variance and the genetics behind it are poorly understood.
1.3 Anorexia Nervosa
1.3.1 Clinical manifestation
Anorexia nervosa (AN) is an eating disorder characterized by severe weight loss. While
mostly achieved by fasting, other behaviors supporting low body weight can be present.
These include increasing energy expenditure by excessive exercise, abuse of drugs that
increase metabolism (e.g. thyroid hormone), or purging, by self-induced vomiting, abuse
of laxatives, diuretics or enemas96. Despite the low body weight, patients present with an
intense fear of gaining weight or being overweight, and are often building their self-worth
on the body weight. A disturbed body image is commonly associated with the disorder97.
Patients often do not recognize the severity of the disorder, even when the weight loss is
life threatening96.
The diagnostic criteria of DSM-V and ICD-10 (cf. A.2) are fairly similar, recognizing
as main points the restriction of energy intake, low weight, fear of gaining weight,
associated behaviors and disturbances in the way the body is viewed. The DSM-V
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further differentiates between restricting type and binge eating/purging type4, diagnoses
defined by the clinical modification of ICD-10 (ICD-10-CM). The DSM-IV criteria also
contained the absence of three consecutive non-synthetically induced menstrual cycles
in menstruating women as a diagnostic criterion, which has been dropped in DSM-V.
DSM-V on the other hand, also defines criteria for partial and full remission32,98.
AN is usually a long-lasting illness, with a median time to remission of about 7 years for
female patients99. It is speculated that one of the reasons behind the long duration of
the illness is the transformation of the behaviors, specifically dieting, from goal directed
(i.e. aiming for a low body weight) to habitual100. The consequences of low body weight and
starvation are manifold: AN starvation is accompanied by a spectrum of secondary effects
that occur either directly due to starvation or result from adaptive processes to starvation.
These are often difficult to distinguish from mechanisms that drive the disorder101.
1.3.2 Epidemiology
AN is known to be a disorder that mostly affects adolescent girls and young women.
However, all ages, sexes, sexual orientations, races and ethnic groups are affected102.
Epidemiological research is complicated by several factors, among other the generally low
incidence, as well as the unwillingness of many patients to recognize the severity of the
disorder and to seek treatment96. Furthermore, cultural aspects also influence the results.
A multi-informant approach together with reliable and valid screening methods are needed
to capture all aspects of the disorder and study its epidemiology96,103.
Epidemiological studies have also struggled with the definition of AN, using either strict
or broad definitions. Broader definition can be achieved by using less severe cutoffs for
BMI, and are more inclusive concerning weight gain, as well as amenorrhea (when using
DSM-IV criteria). Lifetime prevalence using strict definitions is about 0.5-2%104–107, and
reach up to 4.3%106 when applying the broader definitions. Lifetime prevalence in men is
estimated to be below 0.5%107,108.
Depending on the cohort studied, the incidence rates widely differ. In Western countries,
estimates range from about 7 per 100,000 person-years in primary care registries109,110, to
above 200 per 100,000 person-years in adolescent girls105,111.
Sex is the strongest risk factor for AN, with many more women than men being affected by
the disorder. Estimates go from 8:1110, to up to 15:1112 in adult populations. In children
and adolescents, the sex distribution is less skewed113.
Co-morbidities are very common in AN. The life-time prevalence of MDD in AN is
estimated between 60-80% depending on the subphenotype114. Anxiety is also very
prevalent, with estimates ranging from 23% to 75%115. Symptoms of OCD are frequent,
4Binging: Eating large amount of food in a short time, without necessarily being hungry.
16
being present in up to 40-60% of patients116,117, even though most studies report about
25%118. This co-occurrence seems to be at least partly due to a shared heritability between
both disorders119. Alcohol and drug abuse range between 13-24% and 6-18% respectively,
depending on the subtype120. Finally, autistic traits are common in patients with AN121,
and AN and autism co-aggregate in families122.
AN patients have an increased mortality rate compared to the general population123, with
a standardized mortality rate estimated at 5.86. Approximately one fifth of the deaths
are due to suicide124. It is however important to note that recovery is possible, as it is
estimated that up to 60% of patients will recover from AN125,126. However, these estimates
also vary, as the definition of recovery is under debate127. In our studies, we used a common
approach, which considers individuals as recovered when their weight has normalized and
no pathological eating patterns and excessive exercise have been present for more than one
year.
1.3.3 Pathophysiological considerations
For a long time the causes of AN were mainly considered to be psychological. However, in
recent years, biological factors have gained importance. In particular, results from GWAS
based on large cohorts have brought forward new understanding of the mechanisms behind
the disorder. Nonetheless, the pathophysiology is still poorly understood. I will discuss
the most established findings, as well as aspects that are most important for the studies
included in the thesis.
1.3.3.1 Familial and psychological risk factors
As mentioned in section 1.3.2, the highest and best-established risk factor for AN is sex.
It is now well established that social, environmental and behavioral characteristics of the
family cannot be seen as solely causal for AN. Nonetheless, there is some indication that
socioeconomic variables, in particular parental education, are associated with higher risk
for AN126,128.
Personality traits and cognitive styles have been consistently associated with AN,
including weak central coherence129, emotion dysregulation130, impaired inhibitory
control131, perfectionism132, aberrant reward sensitivity133, low-self-esteem134. These traits
are present before the onset of the disorder, but become more prominent during the acute
stages. Some have been shown to affect the prognosis126. It is however important to
underline that the separation between psychology and biology is difficult, as they influence
each other.
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1.3.3.2 Genetics
There is strong evidence that AN runs in families, with AN being 4 times more frequent in
families of patients with AN than in control families135. Female relatives have an up to 11
times higher risk for AN than females that do not have any AN patient in the family136.
Twin studies have estimated the heritability for narrow AN to be between 46-74%137, the
estimates for broad AN being a bit lower (29%138).
As for BD, genetics of AN was initially driven by linkage studies, followed by candidate gene
approaches. These were based on a priori hypotheses, and included genes that were thought
to be biologically relevant, among others GHRL, MC4R, POMC, ESR1, ESR2, FTO,
encoding for Ghrelin, Melanocortin 4 receptor, Proopiomelanocortin, Estrogen Receptors
1 and 2, and Fat mass and obesity associated, respectively139. However, studies were often
underpowered and results did not replicate139.
The advent of GWAS has also pushed the field of AN genetics forward, even if the
cohorts have historically been smaller than in other psychiatric disorders. The first
genome-wide hit was published in 2017 by the Eating Disorder Working Group of the
PGC (PGC-ED)140. This study also showed genetic correlations between AN and several
other psychiatric disorders, but also metabolic traits like BMI, insulin, glucose and lipid
phenotypes. In 2019, combining data from the Anorexia Nervosa Genetics Initiative
(ANGI) and the PGC-ED (16,992 cases of AN and 55,525 controls), eight significant
loci were published42, highlighting the role for MGMT, CADM1, FOXP1, PTPB2.
MGMT encodes for O-6-methylguanine-DNA methyltransferase, a DNA repair protein
involved in defense against mutagenesis141; CADM1 has been associated with BMI by
GWAS and animal models142; FOXP1 has been associated with hippocampal and striatal
development, as well as with body weight in mice143; finally, PTPB2 is implicated in
regulation of splicing141.
Although the estimated SNP heritability was only 11-17% and PRS analyses capture
1.7%, several genetic correlations with psychiatric disorders could be found, including OCD
(r=0.45), MDD (r=0.28), anxiety disorders (r=0.25) and schizophrenia (r=0.25), reflecting
observations from clinical studies. Furthermore, several metabolic and anthropometric
traits negatively correlated with AN, e.g. fasting insulin (r=-0.24) and leptin (r=-0.26),
type 2 diabetes (r=-0.22), fat mass (r=-0.33) and BMI (r=-0.32). Further analyses
revealed that associated genes were enriched in brain tissues, and, on a cellular level,
medium spiny neurons and pyramidal neurons from hippocampal CA1. Overall, the
authors conclude that their result support both metabolic and psychological causes for
AN.
Finally, there is some indication that epigenetic changes could contribute to AN. This is
supported by a family study which found a missense mutation in the histone deacetylase
4 gene (HDAC4 ) segregating with AN, as well as reports on altered methylation patterns
in the HDAC4 locus144.
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1.3.3.3 Imaging
Neuroimaging studies have also brought forward insights into disease mechanisms of AN.
Evidence shows that patients with AN have volume reductions in several brain areas,
affecting both grey (GM) and white matter (WM)145–147. While the support for a reduction
of GM is quite strong148,149, the results on WM are generally more inconsistent149,150. Most
of these changes reversed with weight restoration148,151–153, even if some studies report
persisting differences between AN-REC and controls154. One study by the ENIGMA
consortium evaluating the relationship between genetic variants affecting subcortical brain
volume and those affecting AN, found inverse correlation between the risk for a greater
thalamus volume and risk for AN155.
A recent meta-analysis showed a reduction of global GM in acutely ill AN patients, which
normalized over time after recovery149. The authors report that these changes particularly
affect hippocampal and cingulate regions. However, many of the considered studies were
small and did not correct for age, BMI, nutritional status, and it has been suggested that
the results therefore mainly reflect malnourishment148,149. Controlling for these factors,
some studies have reported increases in grey matter volume in several areas of the brain,
e.g. the orbitofrontal cortex and the insula148.
Regarding WM, significant differences were found in patients with acute AN when
compared to controls, but not after recovery149. Lower fractional anisotropy was found in
several WM tracts, mainly in the fornix and the cingulum, pointing to an involvement of
the limbic system150.
PET studies have mainly focused on serotonin and differences in serotonin receptor in
several brain areas have been shown96. Finally, functional MRI studies have revealed
differences in activation patterns of areas involved in reward processing and cognitive
control156.
1.3.3.4 Endocrine alterations
AN is accompanied by important endocrine alterations, in particular when patients are
underweight96. These affect almost all hypothalamic-pituary pathways157. Regarding
the reproductive system, reduced gonadotropin-releasing-hormone signaling leads to
decreased follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels and
as a consequence low estrogen levels, anovulation and infertility. Puberty can also be
delayed157. The HPA-axis is also often dysregulated, with higher cortisol levels found
in patient with AN than in controls158. Furthermore, high growth hormone levels, low
insulin-like growth factor (IGF)-I, as well as abnormal thyroid hormone levels have been
described159,160. Abnormalities in hormones that regulate appetite have been described,
mostly in line with low nutritional state, even if the signaling seems to be impaired: leptin
levels that normally signal satiety, are low161; ghrelin levels, a hunger signal, are high162.
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Finally, endocrine alterations are also thought to be involved in a higher risk for reduced
bone density and osteoporosis, often present in AN patients163.
Overall, as most of these changes normalize with weight restoration, it is unclear if these
changes are causes or consequences of the disorder.
1.3.3.5 Inflammation
The bidirectional relationship between inflammation and food intake is well established.
Reduced food intake is a common symptom of sickness behaviour occurring during
an increased inflammatory state164 and several cytokines are anorexigenic (e.g. IL-1β,
IL-18165,166). On the other hand, both obesity, as well as malnutrition and wasting have
been shown to be associated with changes in the immune system: While the first is
accompanied by low-grade inflammation167, the second is marked by a weakened immune
system and higher levels of infections168.
It is now well understood that there is strong cross-talk between peripheral inflammation
and the CNS164 and that dysregulated inflammatory processes might play a role in several
psychiatric disorders169. For example, patients with MDD have increased serum levels
of proinflammatory cytokines such as IL-6, TNF-α and CRP, while the strongest genetic
association for schizophrenia is in the major histocompatibility complex (MHC) locus,
pointing to an involvement of the complement system. Furthermore, several psychiatric
disorders have shown genetic correlations with inflammatory disorders, which means that
the genetic risk of one type of disorders increases the risk for the other type67.
Based on these facts one might speculate that AN is associated with a dysregulated immune
system. However, the role of inflammation in AN is not yet well established. For example,
while a bi-directional relationship for risk for eating disorders and autoimmune disorders
has been found in epidemiological studies170, on a genetic level, no positive correlation
with any autoimmune disorder was reported. The only significant correlation to date is a
negative genetic correlation between AN and CRP levels67. Furthermore, autoimmunity
has also been suggested to play a role in the pathophysiology of AN, with auto-antibodies
against a-melanocyte-stimulating hormone, a neuropeptide in the brain signaling satiety
having been described in plasma of patients171. Finally, changes in several cytokines
were shown between AN and healthy controls, two of which (IL-6 and TNF-α) were also
significant in the most recent meta-analysis172. However, it is important to notice that
previous studies on inflammatory markers in AN are scarce and typically based on small
samples.
1.3.3.6 Cell culture
There are only few in vitro studies of AN. Several studies have analyzed in vitro cytokine
production, but there are, to our knowledge, no studies using fibroblasts or lymphoblastoid
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cell lines. One single study was based on iPSC from AN patients (N=7)173. After
differentiation into a mixed neuron population, although no obvious differences between
AN and controls were detected, the authors suggest TACR1 (tachykinin receptor 1) to be
associated with AN, based on pathway analyses and protein measurements.
1.3.3.7 Animal model: The anx/anx mouse
Several animal models for AN exist, including activity based174, stress and diet related175,
as well as genetic models176. Here we are going to shortly discuss the anx/anx mouse, a
model that has been used in our lab for many years and played an important role in the
hypothesis generation for our human studies.
The anx mutation that these mice carry arose spontaneously in a cross from several mouse
strains177, which makes the identification of the exact mutation difficult. Homozygous
mice appear healthy at birth, but start eating significantly less than their heterozygous
siblings, even if they have full access to food177. This leads to gradual emaciation, and the
animals die prematurely around week 3177. This mirroring of core features of the disorder
has led to the mouse being extensively studied as a model for AN. The animals present
with major changes affecting organs, behaviors, metabolic traits and neurotransmitter
systems176,177. Furthermore, several disturbances in the hypothalamus have been described,
including changes in the neuropeptidergic innervation, hypothalamic inflammation, as well
as degeneration176. These were the phenotypes we tried to study in humans in study IV
and V.
1.3.4 Treatment
Recovery from AN is possible: It is estimated that a majority of patients overcome the
disorder, a third show improvements, while about 20% become chronic.178. However, only
a minority of patients will ever seek treatment126. Re-feeding, essential in the treatment
in order to increase body weight, is only the first step in the management of AN. Even if
it is achieved during the admission to a specialized clinic, patients are not always able to
maintain the improved nutritional status96. Psychotherapy therefore plays an important
role and represents the treatment of choice for AN, with several treatment paradigms
available. While family-based treatments have shown the best results in adolescents, there
is no clear gold standard therapy for adults. There is little evidence supporting the use of
pharmacotherapy, with studies on antidepressants and antipsychotics showing no or weak
results on eating habits, weight and psychological comorbidities179,180. However, several
prevention programs have shown promising results in reducing the symptoms in AN and
disorder onset96.
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1.4 Research considerations
1.4.1 Bipolar disorder and anorexia nervosa
BD and AN are separate entities and this thesis does not focus on the overlap between
these two disorders. There are some similarities, as mentioned previously, both being
relatively common and their prevalence often underestimated by the general public.
Furthermore, they are highly heritable, show a certain amount of genetic correlation, as
well as overlap with similar psychiatric disorder (e.g. OCD) and their underlying biology
poorly understood.
Some epidemiological evidence points towards an overlap between the eating disorders
and BD, with eating disorders being common among BD patients181,182. However, this
association seems to be mainly driven by binge-eating disorder and bulimia nervosa
and only to a lesser extent by AN181,183,184. However, the similar comorbidity profiles
(suicidality, mood instability, anxiety disorder), as well as an overlap in symptomatology
(eating and weight dysregulation in BD, mood lability and cyclicity in AN)183,185 underline
the complexity of the relationship, and the need for more research186.
1.4.2 Trait and state
Two further issues to discuss are the distinction between trait and state, as well as between
cause and consequence. A trait is a more stable and enduring characteristic, while state
refers to a temporal way of being, often related to a current clinical state. While the
general genetic liability for BD or AN could be considered a trait, a current manic episode
or low BMI in AN could be considered as a state187. It is thought that markers can be
found for both traits and states. While trait markers are linked to processes that predate
the clinical picture, and even potentially play a causal role, state markers are intimately
linked to a clinical manifestation.
Regarding causality, it is well known that association does not imply causation. While the
associations with markers that cannot change or are unidirectional (e.g. DNA) can more
easily be seen as causal, causality is more complex to establish for many factors (e.g. blood
or imaging markers). It is not possible to sort this out with cohort studies but more
sophisticated research protocols (e.g. longitudinal studies) are needed.
1.4.3 Outlook
Overall, this thesis presents studies covering two different disorders using several
methodologies. These are examples of possible research approaches that break up classical
separations, and integrate different fields to take a larger view at translational research in
psychiatry.
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Chapter 2
Aims
The aim of this thesis was to study the biology related to bipolar disorder and anorexia
nervosa. While studies I to III were mainly focusing on genetics of bipolar disorder,
both in regards to pathophysiology and lithium treatment, studies IV and V aimed at
exploring biomarkers of neurodegeneration and inflammation in anorexia nervosa.
The specific aims of the studies included were:
Study I: To replicate previous findings on the association between subphenotypes of
bipolar disorder and genetic variations in the AKT1 gene.
Study II: To explore the effects of genetic variations in genes involved in glutamate
regulation on glutamate levels in the brain and following up the link to bipolar disorder.
Study III: To investigate the effects of clinical and genetic parameters on lithium
pharmacokinetics in order to better understand lithium biology and improve lithium dose
prediction models for bipolar patients.
Study IV: To investigate the involvement of neuronal degeneration in anorexia nervosa
by studying neurofilament light chain (NfL) in a case-control setting.
Study V: To investigate the involvement of inflammation in anorexia nervosa, by studying
a panel of 92 inflammatory markers in a case-control setting.
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Chapter 3
Materials and Methods
This section includes the description of the cohorts, as well as conceptual explanations
and discussions of the methods used in the thesis. More detailed descriptions of the
methodologies, in particular regarding technical details, can be found in the Material and
Methods section of each individual study.
3.1 Cohorts
3.1.1 Swedish bipolar cohort (Study I, II and III)
This is the main BD cohort our research group has access to and contains today more
than 800 unrelated patients with a diagnosis of BD. Patients were consecutively recruited
from the Unit of Affective disorders, Psychiatry Southwest, at the Karolinska University
Hospital in Huddinge. The collection was started in 2003 and is still ongoing.
Symptoms were recorded according to DSM-IV by a psychiatrist specialized in BD or
a trained psychiatric nurse, based on interview and electronic health records. The data
collected included general demographic information, information on diagnosis (BD type 1
or type 2), age of onset, number and length of episodes and hospitalizations, affected family
members, as well as history of psychosis (including mood-congruency) and rapid-cycling
(Studies I & II). For patients treated with lithium (N = 599), information on lithium
treatment (e.g. number of tablets, lithium concentrations, several variables possibly
affecting lithium levels) were obtained if possible at two or more different timepoints
(Study III). Furthermore, lithium response was assessed and reported according to
the Alda scala, a 10-point scale summarizing changing in illness activity and possible
confounders188. Venous blood DNA was obtained at the time of interview. The collection
was approved by the Regional Ethical Review Board in Stockholm (#01/389, #04-056).
For study I and II, patients were genotyped using TaqMan® SNP genotyping assays
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(cf. 3.2.1). For study III, genotyping was performed in several waves using micro-array
platforms (cf. 3.2.3 and Supplementary Material, Study III).
3.1.2 Mayo Clinic bipolar cohort (Study II)
In study II (cf. 4.2), the aforementioned cohort was combined with the bipolar cohort from
the Mayo Clinic, based on the Individualized Medicine Biobank for Bipolar Disorder, a
collaborative project between the Mayo Clinic, the Lindner Center of HOPE/University of
Cincinnati, and the University of Minnesota. This biobank included adults with clinical
diagnoses of BD type 1, BD type 2 or schizoaffective disorder that were able to give informed
consent. The patients were assessed using the Structured Clinical Interview for the DSM-IV
(SCID). Diagnosis, age of onset, comorbidities, demographic variables, clinical variables,
and illness characteristics (including lifetime history of rapid cycling) were assessed. Only
patients of Caucasian origin were included in the study. Genotyping was performed as
described in 3.2.1. The study was approved by the Mayo Clinic Institutional Review
Board (IRB# 08-008794).
3.1.3 Swedish depression cohort (Study II)
This cohort of patients with MDD (cf. 4.2) was a subcohort of the PART study, a
longitudinal population-based study in Stockholm County, Sweden189. Randomly-selected
Swedish nationals (N=8613) were asked to respond to an extensive questionnaire on
mental health (including the Major Depression Inventory (MDI)), work and relations
twice with a 3-year interval. Individuals were considered as having depression when being
diagnosed with major depression, mixed anxiety depression or dysthymia, in at least
one of the two waves. Diagnosis was set according to DSM-IV, using the MDI. Saliva
DNA were obtained from 5527 participants, including all individuals with a depression
diagnosis (N = 458). Genotyping was performed as described in 3.2.1. The PART study
was approved by the Regional Ethical Review Board in Stockholm (#96-260, #04-528).
3.1.4 MRS cohort (Study II)
Potential participants were referred to the Mayo Clinic and s ened for the presence
of a major depressive episode associated with MDD or BD using the SCID. Exclusion
criteria included the inability to speak English or provide informed consent, the current
treatment with an antidepressant, an history of active substance abuse within the last 6
months, abnormal thyroid-stimulating hormone, unstable medical illness, Young Mania
Rating Scale190 > 12 consistent with hypomania, active suicidal ideation with plan,
current psychosis, and antipsychotic treatment within 4 weeks. Overall, 51 individuals
were included. For 39 individuals, MRS data acquisition, spectra reconstruction and
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quantification were completed. Genotyping was performed for 26 individuals. This study
was approved by the Mayo Clinic Institutional Review Board (IRB# 06-006659).
3.1.5 Lithium pharmacokinetics cohort 2 (Study III)
Participants in this cohort were identified using the Swedish National Quality Register
for BD (BipoläR) (https://bipolar.registercentrum.se/) and those who consented were
included in the SWEBIC-study (Swedish Bipolar Cohort Collection). All patients with
BD who receive treatment at psychiatric outpatient clinics in Sweden can be registered
and followed in BipoläR. The register contains individualized data on diagnoses, basic
clinical epidemiological data, as well as longitudinal data on the natural history and clinical
course of the disease, which can be used for research purposes in a de-identified form. For
study III, the following variables were obtained: age, sex, body weight, height, creatinine
concentration, serum lithium concentration and/or aim serum lithium concentration, when
possible, for several timepoints.
This data was then linked with data from the Swedish Prescription registry, where
information regarding medication collected from the pharmacies (date, package size,
number of packages) is stored. This made it possible to obtain prescription information
on lithium and drugs affecting kidney function (antihypertensives (C09), diuretics (CO3)
and NSAID). For study III, genotyping was performed in several waves using micro-array
platforms (cf. 3.2.3 and Supplementary Material, Study III).
The study was approved by the Regional Ethical Review Board in Stockholm
(#2005/554-31/1, #2008/2009-31/2).
3.1.6 Discovery cohort (Study IV)
Twenty-three patients were recruited at the Stockholm Centre for Eating Disorders (SCÄ).
This included patients with AN (N = 12) and weight recovered patients with a history of
AN (AN-REC, N = 11). In order to be eligible, patients had to be female, 18 years or
older, meeting the DSM-IV criteria for AN, with at least 5 years since AN onset. AN-REC
patients had to have a history of AN according to DSM-IV and recovered normal weight,
defined by BMI > 18, for at least 1 year. Controls (N = 12) were women without own or
family history of eating disorders.
Blood was collected at SCÄ and centrifuged within 2 hours, plasma was stored at -80°C
and shipped on dry ice. NfL measurements were performed at the Clinical Neurochemistry
laboratory at Sahlgrenska University Hospital (cf. 3.4.1).
The study was approved by the Regional Ethical Review Board in Stockholm
(#2012/2007-31/1).
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3.1.7 ANGI-SE cohort (Study IV & V)
This cohort was a subset from the Swedish sample of the Anorexia Nervosa Genetics
Initiative (ANGI-SE), including female patients with active AN (N=113), AN-REC
(N=114) and healthy controls (N=113).
ANGI was so-far the largest international research project on the genetics of AN, including
biological samples and clinical information from more than 13,000 individuals, many of
which were collected at the Karolinska Institutet. These patients were identified through
the National Quality Register for Eating Disorders Treatment, the SCÄ and community
outreach, and screened using questionnaires, including the ED100K (cf. 3.1.7.1)
For the subcohort, the general inclusion criteria for the AN group were an age of 18
years or more, meeting the DSM-IV criteria for AN (with the exception of amenorrhea )
and a minimum illness duration of one year. Individuals in the AN-REC group had to
have a history of AN (according to DSM-IV), restored weight (defined by BMI > 20), no
eating disorder behaviors (e.g. fasting, purging, excessive physical activity) and normalized
eating disorder cognitions. Healthy controls were normal-weight individuals with no record
of disordered eating behavior.
Blood was collected at a hospital near the participants, mailed to the Karolinska Institutet
Biobank and processed upon arrival. Plasma samples were stored at -80°C and shipped
on dry ice. NfL measurements were performed at the Sahlgrenska University Hospital
(cf. 3.4.1). Measurements of inflammatory markers were done by Olink Proteomics
(Uppsala, Sweden) (cf. 3.4.2).
The study was approved by the Regional Ethical Review Board in Stockholm
(#2013/112-31/2).
3.1.7.1 ED100K
ED100K is an online adaptation of the SCID191, aimed at capturing life-time history on
eating disorders192. It includes questions on demographics (age, sex, ethnic background,
first period), a screening part for eating disorders (height, weight, lowest and highest, eating
disorder diagnosis/treatment), and follow up questions on AN. These include questions on
weight and height, period of illness, menstruation, weight and body shape perception,
eating habits and compensatory behaviors.
3.1.8 Limitations
It is important to remember that results based on clinical material can only be generalized
up to a certain point. Indeed, each and every collection of patient material, is biased
and can only represent the people actually recruited into a cohort. Clinical cohorts by
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definition only represent patients that seek help and are willing to participate in research.
Patients not seeking help, as well as those not wanting to participate are therefore not taken
into account and the results therefore have to be interpreted with care. Furthermore,
understanding which patients decline and the reasons behind their decision will lead to
better outcomes, both in research and clinical care193. These are limitations, we have to
address in our clinical cohorts. While it is easier to address for cohort 3.1.1, which has
been well characterized by the clincians and which includes a high percentage of patients
treated at the Unit for Affective Disorders in Huddinge, it is more complicated in regards
to registry based material. Community outreach and screening, as described in cohort
3.1.7 can be one way to address the problem of non-care seeking patients.
3.2 Genetics
3.2.1 SNP genotyping
For studies I and II, TaqMan® SNP genotyping assays were used. This method is based on
polymerase-chain reaction (PCR) using Taq polymerase, which has an intrinsic nuclease
activity.
For each SNP, two probes were designed. These have exactly the same sequence, except
for the interrogated SNP: one probe is complementary to the wild-type allele, while the
other is complementary to the minor allele. The probes are linked to a different fluorescent
dye each, together with a quencher that suppresses fluorescence emission when the probes
are intact. The assays also include a forward primer that guide the polymerase upstream
of the SNP. During the PCR, the probes and the primer first hybridize to the targeted
sites. The hybridized probes are then lysed by Taq polymerase and the fluorescent dyes
are released. Depending on zygosity, either one of the dyes (homozygous individual) or
both dyes (heterozygous individual) are released. At the end of the assay, the fluorescent
signal is measured, and the genotype is determined by software, based on the ratio of the
two samples.
3.2.2 Haplotype estimation
Haplotypes are groups of alleles that are inherited together from a single parent. Identifying
haplotype associations with diseases has been suggested to increase the power of genetic
association studies. Given N SNPs, there are 2N possible haplotypes. For individuals
who are homozygous for all SNPs, the haplotype is unambiguous. For individuals with
several heterozygous loci, the haplotype is ambiguous and the only method to resolve this
ambiguity is sequencing. It is however possible to estimate the probability of haplotypes
in groups of individuals.
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In study I, haplotypes were estimated using the Haplo Stats library194. The estimation is
based on a progressive insertion algorithm, which combines a expectation-maximization
(EM) algorithm, with trimming off pairs of haplotypes with low likelihood. The output
includes posterior likelihoods for each haplotype for each individual, as well as haplotype
estimates over the whole population and subgroups.
3.2.3 Genome-wide association studies
Genome-wide association studies (GWAS), as their name indicate, are studies that test
for associations between a phenotype and genetic variation on a genome-wide level. This
analysis allows for unbiased testing that can give rise to new hypotheses. The phenotype
can be either binary (i.e. a case/control study), in which case a logistic regression is run for
each locus, or a continuous variable, in which case a linear regression model is run. In study
III, we performed the analyses using PLINK version 1.90.b.6.9195, using a linear regression
model, with the first four principal-components as co-variates to correct for population
structure.
3.2.3.1 Microarry SNP-typing
The genomic data necessary for GWAS is created by SNP-typing: Microarrays that contain
100,000 to millions of small beads, each covered by small probes targeting one specific
SNP locus, are incubated with fragmented DNA of the individual to genotype. These
DNA fragments will hybridize with their complementary probe. The probes are exactly
short one base of the SNP locus and can then be expanded using one of four fluorescent
nucleotides. Through laser excitation a color signal dependent on the zygosity (similar
to 3.2.1) is generated and can be associated to each SNP positionally. The genotype for
each SNP is then determined by software, by identifying clusters of samples with similar
intensities196. Several quality control steps are then performed: The data is filtered based
on minor allele frequency (MAF), low calling rates (i.e. SNPs where many samples have
missing information), and samples with low genotyping rate.
Given the structure of the human genome containing regions of high linkage disequilibrium
(LD) (haplotype blocks), it is enough to genotype one index SNP per region that allows to
tag all SNPs that are in high LD. This has led to the fact that common SNP microarrays
contain between 500,000 and 1,000,000 variants and has led to the establishment of
the generally accepted genome-wide significance threshold of 5 · 10−8 197,198. Based on
reference panels produced by projects like the International HapMap Project199 or the
1000 Genomes Project200, it is possible to determine untyped genetic variants (tagged by
the index SNP), a process termed imputation. This is performed using software packages
like IMPUTE2201. This allows for the interrogation of many more SNPs than those that
were directly genotyped.
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3.2.3.2 Summary statistics and interpretation of results
For each SNP tested in a GWAS, the results are reported as a table including information on
each SNP, odds ratios for binary traits, beta-values for continuous traits, as well as standard
error and p-values. These are called summary statistics and can be presented as Manhattan
plots, dot plots showing the approximate position of each SNP on the chromosome on the
x-axis and -log10(p-value) on the y-axis.
The significant markers are not necessarily causal, but most of the time highlight a broader
genomic region that might contain the functional mutation.40. In order to interpret
the results several possibilities exist: SNPs of interest can be analyzed individually, in
regards to their position (i.e. proximity to surrounding genes) or their potential functional
implication (e.g. by testing whether they are expression quantitative trait loci (eQTL),
or whether there is 3D chromatin interaction). Furthermore, tools like MAGMA202 or
PANTHER203 can be used for analysis GWAS results at gene level, as well as gene-set
level. Finally, organ-specific transcriptional data, as well as single-cell data has led to the
possibility to test whether specific organs or cells have a higher probability to be affected
by a set of mutations. In study III, we used FUMA (Functional Mapping and Annotation
of Genome-Wide Association Studies)204, a tool integrating all discussed functionalities, to
follow-up our GWAS results.
3.3 Magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy (1H-MRS) is an in vivo imaging technique. In a
similar way as magnetic resonance imaging (MRI), MRS is based on physical properties
of hydrogen protons and can be used to determine the relative quantity of metabolites,
including N-acetyl aspartate, creatine, choline, glutamate, myo-inositol, lactate, and
GABA205.
An MR signal is created by applying an external static, homogeneous magnetic field
to the area of interest (determined by MRI), and then disturbing it with transversal
radiofrequency pulses. Each proton will elicit a signal based on its chemical environment
(so called chemical shift) that can be detected outside of the body. The key output is an
MR spectrum, a graphical representation with the chemical shift for each proton on the
x-axis and the peak amplitude, proportional to the amount, on the y-axis. This spectrum
is characteristic of each metabolite205. Applying MRS to a brain region (usually a voxel of
approximately 1 cm3), the acquisition spectra will contain information for all metabolites,
which can be used to calculate metabolite concentrations. Specific MRS protocols have
been developed for the quantification of different metabolites206.
Glutamate and glutamine have a very similar structure, which gives rise to very similar
and overlapping spectra. This is why they are often quantified together, a measurement,
30
which is referred to as Glx207. However, with improvements of imaging techniques, it is
nowadays possible to estimate glutamate and Glx separately: In study II, a TE-optimized
PRESS sequence was used to measure Glx208, while a two-dimensional J-resolved averaged
PRESS sequence was used for quantifying glutamate209. Furthermore, measured metabolite
concentrations were corrected for CSF volume to obtain tissue volume corrected metabolite
concentrations used for statistical analyses210.
3.4 Protein marker measurements
3.4.1 NfL measurement
Neurofilament light chain (NfL) plasma levels were measured using monoclonal antibodies
of an established sensitive sandwich ELISA kit (NF-light® ELISA kit, UmanDiagnostics
AB, Umeå, Sweden) on the Simoa platform, a bead based immunoassay platform
(Quanterix, Lexington, MA, USA). Measurements were performed in duplicates in two
rounds (discovery and replication cohort) at the Clinical Neurochemistry laboratory at
Sahlgrenska University Hospital. The intra- and interassay coefficients of variation were
below 7% for the quality control samples.
3.4.2 OLINK
OLINK bioassays are based on the proximity extension assay (PEA) technology using
oligonucleotide labelled antibody probe pairs. When both antibodies bind to the target,
the DNA probes are close enough to hybridize. The probes can be extended by a DNA
polymerase, which leads to the synthesis of a DNA barcode, which can then be quantified
by real-time PCR. This technology allows for the testing of multiple proteins in the same
sample (multiplexing), as each antibody pair is labelled specifically by the DNA probes211.
The obtained data is normalized using internal controls and presented as Normalized
Protein Expression (NPX) units, a relative quantification unit logarithmically related to
protein concentration212
According to the manufacturers, the PEA approach offers the same level of performance as
ELISA and comparable sensitivity to standard ELISA kits with much less sample (1 µL)213.
In study V, inflammatory markers were measured using the OLINK inflammatory panel,
containing 92 preselected markers, covering a wide range of cytokines involved among
others in inflammatory processes. Eighteen proteins were excluded because of high numbers
of missing data (> 20%).
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3.5 Cell culture
3.5.1 Fibroblasts
Skin punch biopsies were taken from the inner side of the arm of the donors after
application of anaesthetic cream. The biopsies were transported to the lab in Dulbecco’s
modified Eagle Medium (DMEM), supplemented with 20% fetal bovine serum (FBS)
and 2% penicillin/streptomycin (P/S). The skin biopsies were cut into small cubes of
approximately 0.5 mm3 and plated onto gelatine coated wells in culture medium consisting
of DMEM supplemented with 2% P/S, 20% FBS and 1% non-essential amino acids
(NEAA)214. The medium was replaced every 2 days. The first keratinocytes could be
observed after 3-4 days, the first fibroblasts after approximately a week (Fig. 4.6, A-B).
When the cells reached confluence, the cells were dissociated and split (Fig. 4.6, C). Cells
were frozen in knock-out serum, supplemented with 10% dimethyl sulfoxide and stored in
liquid nitrogen for long-term storage. Fibroblasts were cultured in DMEM, supplemented
with 1% P/S, 10% FBS and 1% NEAA.
3.5.2 Induced pluripotent stem cells
iPSC were generated as described in Diecke et al.215, transfecting the cells using the
Thermofisher Neon Transfection System with a codon-optimized mini-intronic plasmid that
encodes the canonical reprogramming factors (Oct4, Klf4, Sox2 and c-Myc) together with a
short hairpin RNA against p53. One million fibroblasts were washed in Phosphate Buffered
Saline without calcium and magnesium (PBS -/-) and resuspended in transfection buffer
containing the plasmid. Electroporation was performed according to protocol (1600 V,
10 ms, 3 pulses). The cells were then transferred into full fibroblast culture medium and
plated onto laminin-521 coated plates. After three days, half the medium was replaced
by Essential medium 7 (E7, E6 medium supplemented with 100ng/mL FGF2), sodium
butyrate (0.1 mM) and ascorbic acid (50 µg/mL). Over the following days, half the medium
was replaced on a daily basis. Between day 7-10, the first iPSC were spotted (Fig 4.6, D).
The medium was then changed to Nutristem and changed on a daily basis. Once the
colonies were big enough, they were manually picked under the microscope, transferred
into a single 96-well plate well coated with laminin 521 and expanded (Fig 4.6, E-F). iPSC
were maintained on laminin 521 coated plates in Nutristem, changing the medium daily.
3.5.3 Neural stem cells
Neural stem cell (NSC) lines were generated as follows. In a first step, embryoid bodies
(EB) were generated by culturing stem cells in suspension on a low-attachment plate in the
presence of two SMAD pathway inhibitors to induce neuroectodermal differentiation. Rho
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kinase inhibitor was used for the first 24h. After seven days, the EB were transferred to
adhesive conditions on poly-L-ornithine (PLO) and laminin coated plates. Thereupon, EB
started growing as a monolayer and the formation of neural rosettes became visible after 3-4
days. Neural rosettes were picked up manually and expanded in the presence of epidermal
growth factor (EGF) and fibroblast growth factor 2 (FGF2). NSC were maintained on
PLO and laminin coated plates in DMEM/F12, Glutamax, supplemented with N2 (1:100),
B27 (1:1000), EGF (10ng/mL) and FGF2 (10ng/mL). B27, EGF and FGF were added
every day for the complete volume, cells were split 1:3 upon confluency.
3.6 Statistical analyses
This section covers a selection of the statistical methods used in studies I-V, including
the replication approaches used in study I, linear mixed-effects models (LME), general
additive models (GAM) and cross validation methods used in study III, as well as
quantile regression used in study V. The various forms of classical linear regression
(t-tests, correlations, ANOVA, multiple linear regression), logistic regression, as well
as non-parametric tests (Kruskal-Wallis and Mann–Whitney U test) for p-value based
inference are assumed to be well known by the reader and will not be further discussed.
All analyses were performed in R unless stated otherwise.
3.6.1 Replication
Replication studies are of utmost importance to science, as they provide the standard
by which published claims can ultimately be judged. However, there are several ways to
interpret results from a replication study216,217. You can ask, what is the evidence that a
similar effect as originally reported is also present in the replication study? Furthermore,
one might wonder how consistent the effect size found in the replication study is with
the effect size originally reported? This question is heavily dependent on how one defines
consistency (directionality, effect size. . . )217. Finally, one might also ask what conclusions
to draw when combining the data. Is there a non-zero effect size that can be detected?
How big are these effects? How consistent are the results with one another? However, there
is one important question that cannot be easily answered using classical null-hypothesis
significance testing (cf. 3.6.3): whether to accept the null hypothesis as true. Failing to
reject the null hypothesis is not the same as accepting it217. In the following sections,
several approaches to solve this problem will be discussed.
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3.6.2 Small telescopes
Imagine an astronomer claiming to have found a new planet with a telescope.
Another astronomer tries to replicate the discovery using a larger telescope and
finds nothing. Although this does not prove that the planet does not exist, it does
nevertheless contradict the original findings, because planets that are observable
with the smaller telescope should also be observable with the larger one.
– Uri Simonsohn, Small Telescopes
One such solution is to test whether the effect is small rather than zero. However,
this requires the determination of an effect size that is small enough not to support the
hypothesis any longer, which is difficult, as it is inherently subjective. Simonsohn therefore
suggested the effect size threshold d33% based on power of the original study217: “a small
effect [is defined] as one that would give 33% power to the original study”. Such an effect
would have been too small to be of interest to the authors of the original study and can
therefore be considered a good threshold. Obtaining an effect size smaller than d33% in an
adequately powered replication is equivalent to saying that the effect size was not large
enough to have been detectable by the original sample. To follow up on the telescope
metaphor: d33% corresponds to the size of a planet that is too small to be detected by the
small telescope. If a bigger telescope were to detect a smaller planet, it would be considered
a failed replication. It is however important to note that the concept relies on the fact that
the original study has adequate power for the effect size they are interested in detecting,
which is often not the case in biomedical sciences218.
In study I, we calculated our power to detect d33% in order to determine whether our study
had the size and power to be used as a replication cohort.
3.6.3 Bayesian statistics
In biomedical science, most statistical methods are frequentist methods, which are
inherently linked to the concept of null-hypothesis significance testing and p-values219.
Frequentist statistics are based on long-term frequencies of an event occurring or not,
i.e. calculating the probability of one outcome over a theoretically infinite amount of
repetitions220. In frequentist hypothesis testing, obtained data is analyzed in light of a
null hypothesis of no effect, the p-value being the probability of the data, given that the
null-hypothesis is true. The p-value is then compared to a significance threshold: if it is
smaller, then the data is considered incompatible with the null-hypothesis and the latter
is rejected219.
While frequentist statistics do not attach probabilities to fixed unknown values, but only
to the outcomes of repeatable random events, Bayesian statistics define a possible outcome
parameter value θ given data D as a probability distribution219. A key concept in Bayesian
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statistics is the posterior probability distribution P (θ|D), which is obtained by applying
Bayes’ theorem:
P (θ|D) = P (D|θ)× P (θ)
P (D) (3.1)
In simpler words, the probability of any particular value of θ, given the data D is equal
to the likelihood P (D|θ) times a prior probability P (D), divided by the average likelihood
P (D)221.
Inferential testing can be performed using these posterior probability distributions,
as intervals in which a parameter lies with a certain probability, can be easily
determined219,221.
3.6.3.1 Bayes factor
The Bayes Factor (BF) is a Bayesian alternative to hypothesis testing. When comparing
two hypotheses, e.g. H1 versus the null-hypothesis H0 in light of observed data D, the
Bayes’ factor (BF10(D)) is defined as the ratio of predictive adequacies for the two models.
In other words, the ratio between the likelihood of the dataD givenH1 and the likelihood of
the data D given H0222. When both hypotheses are a-priori as likely, this ratio corresponds
to the ratio of posterior-probabilities.
BF10 is a comparison between two models (note BF10 = 1BF01 ). If BF10(D) = 1, neither of
the hypotheses is more likely to have generated D. If BF10(D) = 4, the data D is four times
more likely to have occurred under H1 than under H0. This characteristic makes the BF
very interesting, as it allows to discriminate between absence of evidence (BF10(D) ≈ 1)
and evidence that would support the null hypothesis (BF10(D)º 1)219.
3.6.3.2 Replication Bayes factor
Based on BF, a so called replication BF has been developed as a means to provide a
quantification for a replication attempt. It is defined as the “change in the Bayes factor
due to the observation of the replication data and quantifies the additional evidence for the
alternative hypothesis given what was already observed in the original study.”216. In other
words, the replication BF allows to compare the predictive adequacy of the sceptic’s null
hypothesis versus an alternative hypothesis that is based on the estimates of the original
study and their associated uncertainty. This also means that a replication BF will favor
the sceptic’s null hypothesis when the effect size of the replication is much smaller than
the original reported effect size.
In study I, BF for contingency tables223 were calculated using JASP224. Replication BF
were computed according to equation 3.2 as described in Ly et al.216.
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BF10(dorig, drep)︸ ︷︷ ︸
Complete BF
= BF10(dorig)︸ ︷︷ ︸
BF original experiment
× BF10(drep|dorig)︸ ︷︷ ︸
Replication BF
(3.2)
3.6.4 Linear mixed effects models
One of the assumptions of linear models is the independence of observations. However,
data often contains clusters, i.e. datapoints are not independent from each other. When
students are sampled from one of several schools, or patients from one of several hospitals,
the assumption of independence is violated. The same is true for longitudinal data, where
data is sampled at several timepoints from the same individual (cf. 4.3). In these cases,
and in particular when there is not the same amount of observations in each group, LME,
or multilevel models, can be used to incorporate a hierarchical structure, which leads to
better estimates of standard errors corrected for non-independence and allows the analysis
of between and within group effects225,226.
LME incorporate fixed and random effects. Fixed effects are parameters that do not
vary, represent the entire population and can be used as explanatory variables. Random
effects are usually grouping factors227 that can be either random intercepts or random
slopes. Random coefficients can capture (unmeasured) variability within each cluste that
creates variation in the outcome, even when all predictors are similar221. These group-level
coefficients can be considered to be drawn randomly from a probability model228, thus the
name random effects (fixed effects being used in contrast). However, many authors agree
that the nomenclature is quite confusing221,228.
In study III, all predictors (e.g. age, height, weight. . . ) were entered as fixed effects,
while person-id was entered as a random intercept. These random effects include the
inter-individual variability, including the variability due to genetic factors that are not
modelled by fixed effects. Their values are also influenced by the amount of observations
for each individual.
3.6.5 Generalized additive models
GAM are an extension of generalized linear models, which include a smoothing function.
Instead of having a constant relationship (β1) between an outcome y and a predictor x1 as
shown in equation 3.3,
y = β0 + β1 · x1 + Ô, Ô ∼ N(0, σ2) (3.3)
this relationship is dependent on a smoothing function f(x), as shown in equation 3.4.
y = β0 + f(x1) + Ô, Ô ∼ N(0, σ2) (3.4)
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This concept is very similar to a relationship that would be described by a quadratic
(x2) or cubic (x3) function, although the function f(x) is usually more complex229. Most
commonly, piece-wise polynomials, so called splines, are used as smoothing functions.
Splines are built up by K simpler base functions that are multiplied by corresponding
coefficients and added together to give the final result. K is referred to as base size, the
higher it is, the wigglier the spline will be230.
GAMs were used in study III: GAMs were tested as smoothing functions for estimating
daily lithium intake from pharmacy data (cf. 4.3.1). In direct comparison to several other
smoothers, a GAM with K=2 gave the best estimates. As can be seen in figure 4.2, the
smoothed result is not very wiggly, but is able to capture changes in the amount of lithium
taken, while not appearing to overfit the data. Increasing to K=3 made the smoother
more sensitive to outliers, which yielded worse prediction results. Splines were also used
to model the non-linear effects of age and eGFR on the outcome variable.
3.6.6 Cross-validation
Cross-validation (CV) refers to model validation to check how results from one statistical
model will generalize to an independent data set. CV is an important technique for
detecting overfitting, a common problem in statistical modelling, and is particularly
important in situation where models are not only used for inferential but also used for
prediction purposes. CV involves the separation of a sample into two complementary
(i.e. non-overlapping) subsets, building a model M in one subset (called the training
set) and testing it in the other (testing set). Testing consists of predicting the outcome
variable based on the predictor variables and the coefficients of the model M . Most of the
time, several rounds of CV are performed, in order to reduce variability221.
Several cross-validation models exist, here leave-one-out (LOO) CV, as well as
out-of-sample (OOS) CV used in study III will be discussed. In the LOO CV, a
sample with N observations, is split into a training set of N − 1 samples and tested on the
sample that was left out. This procedure is repeated N times, after which measures of fit
are calculated by comparing the measured values to the predicted values. In the OOS CV,
a completely different sample that contains the same information as the original sample
used to build the model is used as testing set. This procedure is only performed once and
the measures of fit are calculated221.
Measures of fit depend on the structure of the data and the model. In study III, we report
Root-mean-square error (RMSE) and the Pearson correlation coefficient, as measures of
fit. The RMSE corresponds to the square root of the average of squared errors.
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3.6.7 Quantile regression
Linear models based on ordinary least squares (OLS) methods are used to model the
relationship between the mean of the dependent variable and levels of independent
variables. Several assumptions have to be met in order for the model to work. Alongside
the assumption of independence (cf. 3.6.4), linear models require the residuals to be
normally distributed. Furthermore, when the data is very skewed, or includes many
outliers, modelling the mean might not be greatly informative231,232.
Quantile regression is a regression model that models the relationship between the median
(or any other quantile) and the dependent variables. The model does not rely on any
assumption on residual distribution, is more robust against outliers and allows to explore
relationship in the data that are not represented by the mean, allowing for example to
explore how predictor variables affect the extremes of a distribution231,233. While OLS
methods minimize the sum of the squared errors, median regression minimizes the sum of
absolute errors. While OLS produce an unique solution, quantile regression can have more
than one single solution233.
In study V, 27 markers could not be modelled by linear regression, as the distribution of
the residuals would have been highly skewed. We therefore decided that for those markers,
modelling the median was more informative than modelling the mean. Modelling was
performed using the quantreg package234, p-values were derived by bootstrapping232.
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Chapter 4
Results and Discussion
The studies included in this thesis cover genetic and biomarker analyses on bipolar disorder
and anorexia nervosa. While this section includes a summary of the results, a more
extensive discussion of each study can be found in the respective paper or manuscript.
In a final section, I also shortly summarize non-published data on the establishment of in
vitro models and discuss their potential use in translational psychiatry.
4.1 Study I
The serine/threonine kinase AKT is a central player in intracellular signal transduction,
with a role in many physiological and pathological settings. It is situated downstream
of the phosphoinositide 3-kinase (PI3K): Activation of receptor tyrosine kinases or
G-coupled receptors leads to the activation of PI3K and the production of lipid products
(e.g. phosphatidylinositol (3,4,5)-trisphosphate (PIP3)). These recruit inactive AKT to
the cell membrane, where it is phosphorylated and thereby activated. The signalling
process is terminated by lipid phosphatases acting on the lipid products, as well as
phosphatases that directly dephosphorylate AKT. Hundreds of substrates have so far
been reported, one of the best studied ones is GSK-3β235.
The AKT/GSK3β pathway is well studied in psychiatry. In particular AKT1 is thought
to be involved in the pathogenesis of schizophrenia and psychosis, which is supported by
early genetic studies, post-mortem studies, animal experiments, as well as pharmacological
studies236. Indeed, many antipsychotic medications have an influence on AKT activity
by modulating dopamine signalling237. Finally, lithium, a first line therapy for BD, has
a well-known impact on the AKT/GSK3β signalling pathway, both through a direct
inhibitory effect on GSK3β, but also influencing AKT phosphorylation80.
AKT1 has also been suggested as a risk gene for BD and was originally brought forward as
candidate gene for BD by Toyota et al.238. Karege et al.239 reported several haplotypes in
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AKT1 to be associated with varying occurrence of BD: While the TC haplotype, formed
by the SNPs rs1130214 and rs3730358, was associated with a lower risk for BD, the GC
haplotype formed by the same SNPs supposedly increased this risk. Two years later, the
same group described associations between several SNPs and subphenotypes of BD (based
on history of psychotic episodes)240.
4.1.1 Results
As these studies were based on relatively small samples, we aimed at replicating these
results in a much larger cohort of BD patient (cf. 3.1.1), with information on the same
subphenotypes.
We calculated the power for three thresholds: (1) for the reported main effect sizes, (2) for
an effect size equal to half of the reported size, (3) for an effect size, which the original
studies had 33% power to detect (d33%). This last threshold is based on the concept small
telescopes brought forward by Simonsohn217 (cf. 3.6.2). The idea behind it is that an effect
size that could only be found with 33% power would not be of interest for the original
authors and has been suggested as being a possibility of answering the question whether
the replication study suggests that the effect of interest is undetectably different from zero.
Our study had 99% power to replicate the main effects, above 94% for effect size equal
to half the reported size and above 77% for d33% and we therefore concluded that it was
adequately powered for replication.
None of the results reported to be statistically significant in the original study were
statistically significant in our replication study.
In order to strengthen these findings, we performed a Bayesian analysis, calculating Bayes
Factors (BF) for all comparisons, as well as replication BF (cf. 3.6.3). The BF allows for
a quantification of the support of one model over the other, while the replication BF gives
an information on how much support there is in the new data for a successful replication
of the original data, relative to a failed replication. The BF using default (i.e. flat) priors
supported the null hypothesis in our new data, with moderate to strong evidence. The
replication BF showed very strong evidence against the originally reported effects, favouring
the null hypothesis by a factor between 5 and 1327 times.
In a final step, we studied the results of the latest GWAS for schizophrenia241 and BD44. No
SNP in a 20kb range of the AKT1 gene showed an association with any of these disorders.
4.1.2 Summary
In this study, we were unable to replicate previous results on genetic associations between
BD and genetic variation in the AKT1 gene239,240, using frequentist, as well as Bayesian
approaches, with support from publicly available GWAS results.
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4.1.3 Limitations
On top of limitation addressed in our publication, which include the retrospective
assessment of phenotypes, as well as a lack of information on healthy controls, it is
important to mention that we are fully aware of the fact that candidate approaches are
nowadays outdated. However, as so far GWAS on subphenotypes are scarce, the specific
subphenotypes reported in the original studies have not been studied at all using GWAS
and the original articles are still being cited, we decided it was important to publish this
data.
4.1.4 Personal comments
This study was one of the first studies performed during this PhD thesis and was meant
to build up onto a larger study on the role of AKT/GSKβ signalling, especially in light
of lithium response. However, as the first step, the replication of the studies by Karege et
al. was unsuccessful, and upcoming GWAS studies on BD did not give any indications on
an involvement of AKT1 in BD, we decided to stop the project. The publication process
of this data proved to be difficult. This study exemplifies all projects with negative results,
published or unpublished, that I have encountered during my doctoral studies.
This study is reprinted under the Attribution-NonCommercial-NoDerivatives 4.0 International (CC
BY-NC-ND 4.0) licence.
4.2 Study II
Glutamate is the most abundant excitatory neurotransmitter in the CNS and is involved
in multiple important functions, including synaptic plasticity, memory and learning. The
regulation of glutamate levels in the brain is therefore of utmost importance, especially
as excessive extracellular glutamate levels are considered neurotoxic. This glutamate
excitotoxicity has been associated to several acute (e.g. epilepsy, ischemia), and chronic
brain disorders (e.g. amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s
disease)242. Furthermore, dysregulation of glutamate neurotransmission is thought
to play a role in the pathophysiology of a number of psychiatric disorders, including
schizophrenia, BD and major depressive disorder206. Perhaps the most striking example
of a role for glutamate in affective disorders are the rapid anti-depressant effects of the
N -methyl-D-aspartate (NMDA)-receptor blocker ketamine.
The implication of dysregulated glutamate in the pathophysiology of BD is supported by
several lines of evidence. While post-mortem studies have shown reduced expression of both
ionotropic and metabotropic glutamate receptor subunits in several brain regions243–246,
recent genetic studies have associated several genes involved in glutamatergic signalling
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with BD, for example the NMDA-receptor subunit GRIN2A44 or the SYNE1/CPG2
gene247. Further support comes from imaging studies, in particular 1H-MRS studies
(cf. 3.3). As discussed in section 1.2.3.2, BD has been associated with elevated Glx
and glutamate levels in ACC and prefrontal regions53,54. In contrast to these findings,
meta-analyses on major depressive disorder found lower glutamate and glutamine levels
in ACC248, and the PFC249.
Few studies so far have analyzed the effects of genetics on glutamate levels in the brain,
mostly in the context of schizophrenia spectrum disorders250,251. A recent twin study
analyzed the heritability of several metabolite levels in the thalamus and the ACC in the
context of schizophrenia spectrum disorders. The authors report heritability estimates
of about 0.3 for both glutamate and Glx in the ACC252. In bipolar disorder, a genetic
variation in bcl-2 was associated with changed Glx/Creatine in ACC253, while the val66met
polymorphism in the BDNF gene was associated with changes of Glx/Creatine in the left
hippocampus254.
4.2.1 Results
In this study, we aimed at exploring the effects of genes of the glutamate circle on Glx and
glutamate levels in the ACC and the left dorsolateral PFC in a mixed cohort of depressed
patients. We included SNPs in essential regulatory elements and coding sequences of
GLUL, SLC1A3, SLC1A2, and SLC1A7 encoding for glutamine synthetase, excitatory
amino acid transporter (EAAT) 1, EAAT2 and EAAT5, respectively.
While no difference was found between patient with MDD or BD in any of the regions,
the minor alleles of rs3812778 and rs3829280, two SNPs in perfect linkage disequilibrium
(LD) in the 3’-untranslated region (UTR) of SLC1A2, were associated with elevated 2D
JPRESS mean ACC glutamate levels. No associations were observed for the combined
glutamate/glutamine levels.
In silico analysis using the BrainCloud eQTL browser revealed an association between
the minor allele of rs3829280 and higher levels of CD44, a gene situated downstream of
SLC1A2 on chromosome 1. These results were corrobated by data from the UK Brain
Expression Consortium, where associations in the same directions were found between the
full-length transcript and rs3812778 in the cerebellar cortex, the putamen, the substantia
nigra, as well as in the average of all brain regions.
CD44 codes for a receptor for hyaluron and plays important roles in cell-matrix binding,
signaling, cell migration255, inflammation256 and has been shown to play an important role
in brain development257. Having also been identified as a marker for astrocyte precursor
cells258, we assessed the correlation with several astrocytic markers and markers of the
glutamate-glutamine cycle and found very high correlation of CD44 with markers expressed
in astrocytes (AQP4, GFAP, S100B, GLUL, SLC1A3, SLC1A2, SLC38A3 ), but not with
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Figure 4.1: Pproposed Mechanism for the Impact of Genetic Variations in SLC1A2 on
Glutamatergic Neurotransmission and Rapid Cycling. Figure from Veldic, Millischer et
al., 2019, Translational Psychiatry.
those expressed in neurons (GLS, SLC1A1, SLC1A6, SLC38A1, SLC17A7, SLC17A6,
SLC17A8, and SLC1A7 ).
Finally, to explore potential disease relevance, we followed up the finding in a mixed
cohort composed of both MDD and BD. While no significant difference in the percentage
of minor allele carriers was found between patients with MDD and patients with BD,
patients with rapid cycling BD had a significantly higher percentage of minor allele carriers
(26.9% [95% Confidence Interval (CI): 23.5–30.5]) in comparison to non-rapid cycling
(21.8% [95% CI: 17.9–25.8]) or patients with MDD (21.9% [95% CI: 19.1–24.9]).
4.2.2 Summary
Based on our findings, we propose a mechanism presented in Fig. 4.1. We hypothesize
that the minor alleles of rs3812778/rs3829280 are associated with increased levels of
CD44, possibly a sign of higher numbers of astrocytes. This increase of EAAT-expressing
cells could lead to increased glutamate recycling, dysregulation of glutamatergic
neurotransmission, and increased risk for rapid-cycling. While some of these association
have newly been reported by this study (blue arrows), other associations in this hypothesis
(green arrows) have been reported previously259,260.
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4.2.3 Limitations
There are several limitations to our study. The main one being the small number of
patients included in the MRS study. Furthermore, not all genes that could have an impact
on the glutamate levels were analysed. A replication in a bigger cohort, including a more
complete list of genes (and their genetic variation) is therefore necessary. In order to
address the power problematic, such a study would most probably have to be performed
in a collaborative manner.
Furthermore, 1H-MRS measurements of glutamate have an intrinsic limitation, as this
method captures the total concentration of glutamate in the area of interest, making it
difficult to separate (1) intra- and extracellular glutamate, as well as (2) glutamate used
for metabolic functions from glutamate used as neurotransmitter53.
Finally, there is some heterogeneity in the diagnoses of BD and MDD. While BD diagnosis
was based on medical interviews, medical records and questionnaires performed in clinical
settings, MDD cases where selected from a population cohort using the Major Depression
Inventory.
This study is reprinted under the Attribution 4.0 International (CC BY 4.0) licence.
4.3 Study III
Pharmacokinetics is the study of the fate of pharmacological substances in the body,
describing their absorption, distribution, metabolism and excretion. Traditional
pharmacokinetic studies are usually based on repeated measurements from the same
individual at fixed time-intervals after a given dose. These studies often only include few
patients and are used to calculate pharmacokinetic parameters such as bioavailability
or clearance. In contrast to this, population pharmacokinetic studies are based on
measurements from patients treated with the drug. Although they require much larger
cohorts, fewer measurements per patient are needed. Furthermore, this study design
allows one to distinguish between inter- and intra-individual variability and makes the
analysis of co-variants (e.g. age, sex, kidney or liver function) possible261,262.
In this study, we used a population pharmacokinetic approach to investigate lithium
pharmacokinetics, using the log-ratio between serum lithium (SL) and daily lithium
intake (DLI) as outcome of interest. This ratio corresponds to the inverse of
log(lithium total body clearance) at steady state, assuming a bioavailability of 100%.
Lithium pharmacokinetics is a well-studied field, both at individual and population level.
However, most of the studies were based on small sample sizes and genetic effects have so
far not been studied. In order to achieve enough power to perform a GWAS (cf. 3.2.3), we
therefore based our study on two Swedish cohorts (cf. 3.1.1 and 3.1.5), including overall
5759 observations from 2452 bipolar patients treated with lithium.
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Figure 4.2: Prediction model to estimate daily lithium intake based on amount of lithium
collected at pharmacies. A Building the model. Column 1: Examples of the relationship
between daily lithium intake (DLI) from the electronic health records (EHR) and the mean
DLI per prescription. Column 2: Relationship between DLI (EHR) and DLI (prescription)
after outlier removal. Colum 3: Relationship between DLI (EHR) and estimated DLI using
a generalised additive model (k=2). B Applying the model. Exemplified application
of the model on the data of cohort 2 after outlier removal. Figure from Millischer et al.,
manuscript.
4.3.1 Estimation of daily lithium intake from prescription data
In cohort 1, we had access to the patient’s electronic health records (EHR) and therefore to
the information on the number of tablets prescribed. In cohort 2, based on register data,
we only had access to the information of the Swedish prescription registry and therefore to
the amount of medication collected at the pharmacies (date of purchase, size and number
of packages collected). In a first step, we therefore built a prediction model to estimate
daily lithium intake based on this data in cohort 1 (exemplified in Fig. 4.2).
After collecting both type of information from 87 patients from cohort 1, we calculated
the mean daily lithium intake per prescription period (mean DLIprescription) by dividing the
total amount of lithium prescribed by the time until the next prescription (Eq. 4.1).
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meanDLIprescription =
ntablets.moltablet
timeprescription
(4.1)
Column 1 in Fig. 4.2-A shows the relationship between this estimate (red line) and the
DLI recorded in the EHR (‘DLI (EHR)’, blue line). After removing outliers (column 2,
orange line), we tried several smoothing models (median, mean, LME, GAM) in a training
set (N=60) and tested the best two in a testing set (N=27). The best fitting model was
the GAM with k=2 (column 3, green line), with a RMSE of 6.716, which corresponds to
an error of approximately one tablet of lithium sulfate. This model was then applied on
all patients in cohort 2 (Fig. 4.2-B). An estimated DLI value was thus obtained for all
timepoints in the quality registry between the first and the last lithium prescription.
4.3.2 Influence of demographic, physiological and clinical
parameters on log(SL/DLI)
We first studied the effects of demographic, physiological and clinical parameters on
log(SL/DLI), which allowed us to replicate several well-established findings. In univariate
analysis using a LME (cf. 3.6.4) with individuals as random effects, we could show
associations between log(SL/DLI) and age, sex, body weight, height, estimated glomerular
filtration rate (eGFR), serum lithium level, co-medication with diuretics (excl. potassium
sparing agents) and agents acting on the renin-angiotensin-aldosterone system (RAAS).
The effects were very similar in both cohorts, providing evidence that the estimation of
DLI in cohort 2 was correct.
These results indicate that older patients, women, patients with reduced kidney function,
lower body mass, as well as patients taking diuretics or agents acting on the RAAS require
lower doses of lithium. Furthermore, the positive association between SL and log(SL/DLI)
is an indicator that increases in DLI are not linearly associated with increases in SL. In
other words, in order to increase SL from 0.4 to 0.5 mmol/L a higher increase in DLI will
be needed than to increase SL from 0.8 to 0.9 mmol/L. This effect was not only observed
at the sample level, but also within individuals.
A LME including all predictors as fixed effect and individuals as random effects explained
63% and 47% of the variance of log(SL/DLI) in cohort 1 and cohort 2, respectively, with
marginal effects being very similar between both cohorts. Cross-validation in a leave-one
individual out (LOO), as well as an out-of-sample (OOS) fashion (cf. 3.6.6) showed good
fits for both models.
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4.3.3 The influence of genetic factors on log(SL/DLI)
In the next step, the random effects of the previous model were used as the dependant
variable in a GWAS. These random effects represent the individual-level effects in the
SL/DLI ratio after accounting for the above-mentioned co-variates. In other words, they
represent the inter-individual differences that are not explained by any of the predicting
variables. These are – at least partly – due to genetics. A GWAS was run in both
cohorts separately, including the four first principal components as covariates to control
for population substructure, followed by a meta-analysis.
No locus was found to be significant at genome-wide significance level, in either of the
cohorts separately or in the meta-analysis. Nine genomic loci showed an association at
p < 10-6 in the meta-analysis; the strongest one was rs61761173 on chromosome 1 in an
intronic region of MEGF6 (p=1.10-7).
A gene-based analysis using MAGMA revealed the gene QSER1 to be significant after
correction for multiple testing (padj=0.036). Although its function is currently unknown,
QSER1 was found to be associated with diabetes and obesity in several studies263–265.
Interestingly, the third strongest association was for FTO, a gene that has also been
associated with several metabolic traits (e.g. type II diabetes266, body fat percentage267).
These results would support the hypothesis that genes affecting body composition have an
impact on log(SL/DLI). Finally, gene ontology analysis of 27 genes that were prioritized
using FUMA204 showed an enrichment for genes involved in metal homeostasis. This result
was mainly driven by a number of genes in the metallothionein (MT) family. Present in all
tissues, MT are able to bind transition metal ions with high affinity, and are involved in
the response to zinc, copper, and cadmium ions. Even though, so far, binding to lithium
has not been shown, an implication of MT in lithium metabolism seems plausible.
4.3.4 Prediction algorithm
Based on these results, we developed an algorithm to predict the amount of lithium needed
to reach therapeutic levels, including the eight parameters described in section 4.3.2. As no
single genetic variable with a big effect size was found to influence log(SL/DLI), we decided
not to include genetics into the prediction model. Indeed, even though the inclusion of a
polygenic risk score (PRS) based on our results might improve the model, performing a
full genotyping of patients before starting lithium therapy seemed clinically unfeasible.
The algorithm has been implemented as an interactive shiny app268, currently available
upon request and requiring R-studio to run. It requires the input of sex, age, weight, height,
plasma creatinine, co-medication, as well as the required serum lithium concentration and
the lithium preparation. The output comprises (1) a summary of the input including
the eGFR from creatinine input (top table), (2) a table giving the approximate amount
of tablets needed to reach different serum concentrations, as well as the 95% prediction
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Figure 4.3: Using the prediction algorithm to predict the amount of lithium needed for an
elderly woman with chronic kidney disease.
interval (PI) (second table), (3) a graphical representation of the same information, and
finally (4) a written sentence as summary.
Two examples are shown here in fig. 4.3 and 4.4. While fig. 4.3 shows the prediction for
an elderly woman with chronic kidney disease (0.89-2.07), fig. 4.4 shows the prediction
for a young, healthy but overweight man (4.05-9.24). As expected, given the amount of
variance explained by the model, the prediction interval is relatively large. Furthermore,
it is worth noticing that the prediction line shown in the graphical representation is fairly
flat. This effect is due to the non-constant relationship between log(SL/DLI) and SL
(cf. 4.3.2) in our model, which predicts a sharp increase of SL above a certain threshold
of DLI. The mean error in predicting DLI estimated from the LOO cross validation is
about 6 mmol. Although these errors show that our model is too uncertain to blindly
rely on the algorithm, we think that it could provide a useful guideline for clinicians, by
summarising data that is collected before starting a lithium therapy in an evidence-based
matter. Having a theoretical target value for the amount of lithium needed from the
beginning could eventually lead to a shorter time needed to reach therapeutic levels, as
well as reduced adverse events due to too high SL levels. The usefulness of the application
has yet to be determined in a prospective study.
4.3.5 Concluding remarks and future plans
This is the first study combining classical pharmacokinetic approaches with a GWAS to
study lithium pharmacokinetics. Although no single locus was found to be significant, the
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Figure 4.4: Using the prediction algorithm to predict the amount of lithium needed for a
young healthy man.
analysis of the GWAS results uncovered several interesting findings, not least that there is
no single genetic variation with a large effect size influencing log(SL/DLI). Furthermore,
we were able to confirm several known findings in the biggest pharmacokinetic study on
lithium so far, and use these results to build a prediction algorithm. In order to strengthen
these results and bring them closer to clinical application, we are planning several follow-up
projects.
The prediction algorithm will be validated in two phases. In a first phase, we have started to
collect data from lithium naïve patients during lithium therapy initiation until steady-state
is reached. The analysis of this data will allow us to determine whether the algorithm
works in a prospective way, i.e. whether the variables before treatment have the same
explanatory power for log(SL/DLI), as when collected simultaneously. In a second phase,
we will perform a prospective study: We will compare the time needed to reach therapeutic
levels and the number of adverse events during lithium therapy initiation with and without
the use of the prediction algorithm. If the efficiency of the tool can be validated, it would be
easy to implement in clinics, providing a method to a personalizing treatment in psychiatry.
Regarding the genetic part of the study, we are planning to first cross-validate the genetic
results using a PRS calculated from each cohort independently in the other cohort to see
how strong the explanatory power would be. In a second step, we will try to increase our
sample size by contacting our collaborators in the ConLiGen. Given our results, we are
positive that increasing the sample size will lead to the discovery of genome-wide significant
results that could then eventually be used to improve the prediction algorithm.
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4.3.6 Limitations
There are several limitations to the study. The estimation of DLI in cohort 2 introduces
some variation, however, as the results for both cohorts were very similar, we are
confident in our results, even though some variation remains unaccounted for. Also, some
variables that probably influence our outcome of interest are missing: NSAID intake,
morning/evening intake of lithium, as well as the interval between the last lithium intake
and blood draw. The use of NSAID is not possible to correct for when being bought over
the counter. However, lithium treated patients are strongly advised against using NSAID
without prescription and prescribed NSAID did not appear to influence log(SL/DLI).
Furthermore, we only had information about the total daily amount of lithium and not
how many tablets are taken mornings and evenings. This might influence the lithium
levels the next morning: for the same number of tablets daily, a patient taking more in
the evening might have slightly higher levels in the morning than a patient that takes
more in the morning. Finally, patients are advised to draw blood exactly 12 hours after
the last lithium intake, however, this is not always possible. We estimate however that
given the known half-life, a couple of hours will not significantly influence SL levels.
4.4 Study IV
Neurodegeneration is a process present in many neurological disorders, both in classic
neurodegenerative disorders, e.g. Alzheimer’s disorder269, amyotrophic lateral sclerosis270,
Parkinson’s disorder271, but also immune mediated disorders like multiple sclerosis272.
Neurodegenerative processes have also been suggested to play a role in psychiatric disorders,
like BD31. As described in section 1.3.3.3, volume reductions in several brain areas affecting
both grey and white matters have been described in patients with AN and point toward
possible neurodegenerative processes associated with AN.
Neurofilaments are intermediate filaments exclusively located in the cytoplasm of neurons,
which provide structural stability to neurons. They are formed by three types of subunits,
neurofilament heavy chain, medium chain and light chain (NfL)273. NfL is the most
common and most soluble of the subunits, which makes it easily measurable in both
CSF and peripheral fluids and therefore a good candidate biomarker for neurodegenerative
processes273. Indeed, even though NfL is constantly released into the CSF at low levels
in an age-dependant manner274, this release increases sharply during inflammatory or
neurodegenerative processes275, as well as during traumatic or vascular brain injury274.
Based on these properties, NfL has been extensively studied and associations with several
neurodegenerative disorders have been established, among others with multiple sclerosis276,
Alzheimer’s Disorder277, frontotemporal dementia (FTD)278, traumatic brain injury279.
Interestingly, NfL has been brought forward as a potential biomarker to distinguish FTD
from AD, as well as from psychiatric disorders that would mimic FTD symptoms273. As
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for psychiatric disorders, elevated NfL levels have been reported in the CSF of patients
with BD280.
4.4.1 Results
We measured NfL in the plasma of patients with AN, patients that had recovered from
AN (AN-REC), as well as healthy controls in two different cohorts in an attempt to better
delineate potential neurodegenerative processes in AN.
After replicating the previously published association between NfL levels and age, we
report higher levels of NfL in plasma of patients with AN compared to healthy controls
and to AN-REC in both cohorts. Higher levels of NfL in AN-REC compared with controls
were observed only in the larger replication cohort. Furthermore, we found a negative
association between NfL levels and BMI across all samples. Interestingly, the slopes of
the association were significantly different in the AN group compared to both AN-REC
and controls: NfL levels increase sharply with lower BMI below a BMI of 18.5. This is an
indication that the increases in NfL levels observed in AN are not only a linear effect of
lower BMI, but that separate or accelerated processes appear below a certain threshold.
Overall, our results show that elevated levels in active AN might normalize somewhat
with weight recovery. The 2-fold increase observed in AN patients is however lower than
the observed changes in MS281 and corresponds roughly to the increase observed in mild
traumatic brain injury in boxers282. It has however to be noted that comparisons across
studies have to be performed with care.
The origin of this increase can only be object of speculation. Even if serum and plasma
concentrations of NfL are not influenced by blood-brain-barrier integrity283, correlate highly
with concentrations in the CSF277,281,283, increased peripheral NfL levels could also come
from peripheral nerve damage. The central origin of NfL seems nonetheless an appealing
hypothesis, and would be supported by imaging studies, as well as the neurodegeneration
seen in the hypothalamus of the spontaneously anorectic anx/anx mouse (cf. 1.3.3.7).
There are, to our knowledge, two previous studies that analysed possible markers
of neuronal damage, including S100B284, glial fibrillary acidic protein (GFAP) and
neuron-specific enolase285. However, no changes in the levels of these markers was
observed between patients with AN and controls. This could be due to smaller sample
size, or to different mechanisms leading to the increase of these markers. Indeed, S100B
was not elevated in traumatic brain injury279 or BD280, while NfL was.
4.4.2 Limitations
There are several limitations in our study. Although our study supports the hypothesis that
neurodegenerative processes occur during the acute phase of AN, the lack of synchronized
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imaging on the same individuals makes it impossible to determine where these processes
are actually occurring. A parallel measurement of NfL in CSF would also have been an
advantage. Furthermore, our study was cross-sectional, which makes conclusions on the
development over time more difficult. This is especially true for the recovered group: Even
though a normalization after weight gain seems plausible, we were not able to conclude
anything on the time course of this effect, as the information on length of recovery was
not available. Finally, as for many other studies on AN, it is impossible to determine
whether the observed effect is due to the low BMI or an AN-specific process. Including
constitutionally lean individuals might help clarifying this problem.
4.4.3 Concluding remarks and future plans
This is the first report on elevated NfL levels in AN compared to healthy controls, as well
as AN-REC, pointing toward neurodegenerative process in the active illness, which might
be attenuated upon recovery.
In a next step, it will be interesting to analyse NfL levels in a longitudinal manner, in order
to define the development over time after recovery and assess whether increased NfL levels
can be used as predictors for recovery. It would be of particular interest to measure NfL
levels, both centrally and peripherally, in patients undergoing imaging analyses in order to
determine the origin of the increased NfL levels.
This study is reprinted under the Attribution 4.0 International (CC BY 4.0) licence.
4.5 Study V
Building on the potential role of inflammation (cf. 1.3.3.5) and markers seen in anx/anx
mice, we decided to further investigate the role of inflammation in AN. Using the
inflammation panel from OLINK (cf. 3.4.2), we measured a broad array of inflammatory
markers in the plasma of a large sample of persons with AN, AN-REC and healthy
controls. After quality control, we included 74 markers in our analysis.
For each one of these markers, we assessed group differences (i.e. comparing AN, AN-REC
and controls), as well as associations with BMI. In order to assess whether the associations
with BMI were linear (in a similar way as described in section 4.4), as well as to make a
comparison with earlier studies that do not include patients with low BMI, we analysed
the BMI over the whole range, as well as in the AN-group (BMI < 18.5) and the non-AN
group separately (BMI > 18.5). Many of the marker levels were not normally distributed.
Being log-transformed, we opted for using quantile regression (cf. 3.6.7) in order to model
the median instead of the mean for those markers.
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After Bonferroni correction, we report 19 proteins to be significantly lower in AN compared
to controls, most of which were also significantly lower between AN and AN-REC. Six
proteins had significantly higher plasma concentrations in AN compared with controls,
three of which were also significant between AN and AN-REC. Not a single marker was
significantly different between AN-REC and controls (Fig. 4.5 A).
Furthermore, we report twenty-five proteins with a positive correlation with BMI and four
proteins with a negative correlation over all samples (Fig. 4.5 B). Interestingly, while most
of the markers with a positive correlation (column B, blue) over all samples also showed
some correlation with BMI in the subgroup of patients with BMI > 18.5, none of the
markers with a negative correlation over all samples (column B, orange) appeared to be
correlated with BMI in the said subgroup.
It is important to note that many of the inflammatory cytokines also have other roles
not directly linked to inflammation. This is well exemplified with a subgroup of proteins
involved in bone physiology that we have found to be different between AN and controls
(OPG, TRANCE (RANKL), CSF1 (MCSF) LAP-TGFβ, and CST5). Low bone mineral
density and increased risk of fractures is a common complication of AN163. This could be
caused by decreased estrogen concentrations, low BMI, elevated cortisol levels, low IGF1
levels, as well as poor nutrition and a lack of vitamin D163. Some evidence indicates that
body weight restoration can reverse bone loss, which is supported by our findings163. While
being indicative of a disturbed balance between bone formation and resorption in acute
AN, none of these proteins differed between AN-REC and controls, suggesting that these
effects are reversed upon weight gain/restoration even though although longitudinal studies
are needed for confirmation.
4.5.1 Limitations
There are similar limitations in this study as in study 4. Despite being one of the first
studies to include an age-matched group with women who had recovered from AN,
the cross-sectional design of our study cannot establish cause and effect. Also, the
differentiation between state (low BMI) and trait (AN) is difficult without constitutionally
lean individuals, even if the result of our study would support the state hypothesis for
most markers—as no differences between AN-REC and controls were seen. A longitudinal
study following persons with AN during the course of recovery is necessary to address
both of these problems.
4.5.2 Concluding remarks and future plans
This is, to our knowledge, the largest study on inflammatory markers in AN, both regarding
sample size and number of markers studied. We report an aberrant inflammatory profile in
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Figure 4.5: Plasma protein concentrations changed in AN vs. controls, AN vs. AN-REC,
AN-REC vs. controls (A), associations between plasma protein concentrations and BMI
(B). Colors indicate the direction of change, intensities the statistical significance. AN
= anorexia nervosa, AN-REC = recovered from anorexia nervosa, CTR = normal weight
healthy control.
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patients with active AN, but not in patients that have recovered from AN. In parallel, we
report that many of the inflammatory proteins correlate with BMI, corroborating several
previous findings, but also bringing forward new ones. Even if the causal relationship is
still not completely established, we hypothesize that normalizing the inflammatory profile
in AN is desirable to reduce long-term effects, underlining the importance of providing fast
and adequate treatment to patients with the disorder.
We are currently planning to follow-up the results of this study in a two-fold way. First,
we will combine our dataset with PRS of AN, BMI, as well as the available PRS of marker
levels. Finding associations between the genetic liability of AN/BMI and marker levels,
or the genetic liability for increased levels of inflammatory markers and AN could allow
us to draw conclusion on the directionality of the associations reported in this study.
Furthermore, we are planning to measure the same panel in a longitudinal cohort including
patients with AN during treatment. This will allow us to determine the exact timeline of
protein changes, as well as testing whether more severe changes in inflammatory markers
are associated with a slower recovery.
4.6 In vitro models in psychiatry
One aim of my PhD education was to establish and use cellular models of psychiatric
disorders. This part of the project included (1) the taking of skin biopsies and derivation
of fibroblast lines from patients; (2) the establishment of induced pluripotent stem cell lines
from patients; (3) the derivation of neural stem cell lines from patients that could (4) finally
be used as in vitro models of lithium response in BD. We were able to establish several
protocols (including biopsy collection and processing, iPSC derivation, NSC derivation),
as well as the development of new protocols (including serum-free culture of fibroblasts
and simple organoid usage). However, much of the data is not yet in manuscript form and
this project will be continued in collaboration with several other groups. In this section, I
will present a short summary of the aims and the achieved results.
4.6.1 Fibroblast collection and establishment of iPSC lines
We established the collection of skin biopsies at Psychiatry Southwest, Karolinska
University Hospital Huddinge, with the aim to collect 20 patients, 10 lithium-responders
and 10 non-responders. We screened for patients in the bipolar cohort (cf. 3.1.1),
based on Alda-scores. Inclusion criteria were BD type 1 and a family history of BD or
schizophrenia. Lithium responders were defined as having a total Alda score ≥ 9, lithium
non-responders as having an Alda score A ≤ 3. The recruitment process was considerably
longer than expected until 17 sex-matched patients that met the criteria (8 responders,
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Figure 4.6: Examples of the steps in establishing fibroblast and iPSC lines. (A) Day 8 after
plating the biopsies: After keratinocytes, the first fibroblasts migrate out of the biopsy.
(B) Day 14: Fibroblasts form a confluent layer around the biopsy. (C) Fibroblasts after
the first splitting. (D) Day 10 after transfection: The first iPSC colonies appear. (E)
Day 2 after picking the colony. (F) Day 8 after picking the colony. Legend: *: biopsy, k:
keratinocyte, f: fibroblasts, i: iPSC.
9 non-responders) were included. Although exact age matching was not possible, we
obtained samples with similar age distribution.
Fibroblast lines were derived as described in section 3.5.1, expanded and three vials of each
patient were cryopreserved (Fig. 4.6). We then established the protocol to derive iPSC in
the lab (cf. 3.5.2) and were able to derive iPSC from a couple of patients (Fig. 4.7).
4.6.2 Development of a serum free fibroblast culture medium
A secondary aim was to find a metabolic signature for lithium response using mass
spectrometry on samples obtained from untransformed fibroblasts of lithium responders
and non-responders.
In order to achieve this, we first had to develop a serum-free and chemically defined medium
to culture skin fibroblasts: Indeed, FBS, which is commonly used for fibroblast culture,
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Figure 4.7: Basic characterization of one iPSC line by immunofluorescence, staining for
the pluripotency markers OCT4, SOX2, c-MYC and SSEA4, nuclear staining using DAPI.
Scale: 100µm.
represents an important obstacle in mass-spectrometric analysis, due to the high levels of
proteins and metabolites present. We were able to define a protocol to adapt human skin
fibroblasts to serum-free conditions (data not shown, manuscript under review). Although
the proliferative potential of the cells was significantly reduced, the fibroblasts survived
up to 6 weeks under these conditions. Furthermore, we were able to show that significant
differences could be detected using mass-spectrometry when comparing the supernatant
after three days in contact with the cells with fresh medium. This proof of concept
confirmed active metabolism in cells, as well as the robustness of the cell medium for
analyses using mass-spectrometry.
We then applied the protocol on the 17 patient fibroblast cell lines. In a first step, we
adapted 6 wells of a 6-well plate to the serum-free medium, followed by a 2-week period
where half the wells were treated with 1 mmol/L of lithium, and half were not. After
2 weeks, the medium was not changed for 3 days in order to increase the concentration
of secreted metabolites. The supernatant, as well as the cells were then collected and
snap-frozen.
The samples were then sent to the San Raffaele Scientific Institute in Milan for mass
spectrometric analyses of the exo- and the endometabolome. However, due to technical
delays, the final results have not been obtained yet.
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4.6.3 Establishing neural stem cells
The third subproject was the generation of NSC. We were able to establish a protocol for
NSC derivation and derive and characterize NSC from a human embryonic stem cell line
(hES), as well as from iPSC. Characterization included karyotyping and gene expression
analysis of the NSC, pluripotent and NSC marker analysis at protein level. Furthermore,
we analysed the differentiation potential of NSC into neural and glial cells, as well as
neuronal activity in mature neurons using electrophysiology (data not shown, manuscript
in preparation). Using this protocol, we studied the effects of short-chain fatty acids on
NSC and were able to show that treatment with acetate, propionate and butyrate at
physiological levels led to an increase in cell proliferation286. The NSC are currently used
by collaborators in two further projects.
4.6.4 Concluding remarks and future plans
This part of the project was an important part of the education and had several positive
outcomes. In particular, I increased my knowledge on cell culture (fibroblast, hES, iPSC,
NSC), molecular techniques, and, most importantly on planning and performing cell studies
in psychiatry. As co-supervisor of two master students working on the projects, I got
experience in teaching and supervision. Finally, the work on these projects led to the
writing of a book chapter on cell models of mood disorders in an upcoming book on
translational psychiatry.
Several manuscripts are in preparation and will be published in the coming year. Regarding
the use of the patient derived cells, we are currently planning to start collaborations with
established actors in the field.
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Chapter 5
Concluding remarks and future
perspectives
5.1 Concluding remarks
There are three themes covered by the studies included in the thesis that I will highlight
and discuss: replication, integration and translation.
5.1.1 Replication
Replication is the gold standard by which scientific claims can be tested. If results are
based on an effect that is real, it should be possible to replicate them, as long as similar
procedures are used in cohorts with adequate power.
There is a replicability crisis affecting psychological and biomedical sciences287,288, and
several solutions have been suggested to tackle it, for example using lower threshold for
p-values instead of the widely accepted α=0.05, or abandoning the concept all together289.
Even if, in psychiatric genetics in particular, the use of more conservative threshold has
led to clear improvements, replication remains an important tool in the advancement of
science.
Several of the presented studies touch on the subject. Study 1 is a direct replication study
of previously published results. In study 3, we were able to replicate previously published
results, as well as validate our findings in two separate cohorts, providing replication within
the study. The genetic findings are however in need of replication, which we are aiming
for in our future plans. We will test the explanatory power of PRS built on the cohorts
separately, as well as aim at replicating the findings in a larger cohort in collaboration with
ConLiGen. Finally, study 4 is also based on a discovery and a replication cohort.
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Regarding study 2, although support for the eQTL came from two different sources, the
main findings require replication in larger cohorts. The importance of such replication
studies became particularly clear when writing a systematic review about SLC1A2/EAAT2
in mood disorders. Although there has been a large amount of research on the subject,
few studies report replications, meta-analysis was not possible and the overall role of the
gene in mood disorders remains to be determined290.
A common problem that arises is the difficulty to publish replication studies and negative
results, replication studies often being published in journals with much lower impact than
the originally reported results291,292. One consequence is the commonly known publication
bias, which makes the interpretation of results more difficult.
5.1.2 Integration and collaboration
Several forms of integration have been important for this thesis, including integration of
methods, cohorts and research fields.
The advantages of combining and integrating cohorts have been mentioned in several
previous sections. The fact that our research group has been contributing data to both
the Bipolar Working Group of the PGC and ConLiGen for several years has shown me
the importance and advantages of collaborations and how they can drive science forward.
Being part of it feels of utmost importance.
At a smaller scale, we have aimed at doing this in study 2, by combining our efforts with
researchers from the Mayo Clinic, in study 3, with the researchers from the Department of
Medical Epidemiology and Biostatistics around the BipoläR register, in study 4, with the
ANGI-SE cohort, which finally also enabled study 5. We are planning to follow a similar
path for our cell studies, where we are currently exploring possibilities in joining a larger
collaboration.
Another form of integration that enabled many of the studies was the discussion across
research field borders. Indeed, the NfL project was empowered by the close collaboration
with researchers from the multiple sclerosis field, in which NfL has for a long time been
established as biomarker. Many statistical methods found their way into my studies
through discussion with researchers with psychology backgrounds and from the PET group,
much more used working on Bayesian statistics, cross-validation and modelling17.
Finally, the integration of several methods has been important in the thesis. While maybe
not allowing for particular specialization, a basic understanding of diverse methodologies
might be an advantage for an aspiring clinician-scientist interested in translational research.
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5.1.3 Translation
Translational approaches were important in all studies and discussed previously. However,
two aspects should be highlighted.
Studies 4 and 5 are examples of the translation from bench-to-bedside, as the research
interest leading to the main hypotheses mainly originated in phenotypes observed in
the anx/anx mouse model. Although our research approach allowed us only partially
to translate the findings in mice, as blood can only reflect processes happening in the CNS
in a limited way, our studies clearly indicate the potential of weaving together pre-clinical
and clinical findings.
Study 3 exemplifies translation in the opposite direction, going from bedside-to-bench.
Indeed, I became aware of the problem of lithium dosage while working in the clinics. The
results from the genetic study do not point towards a single target that could increase
the prediction potential enough to be used in clinics. However, if the predictive validity
of a PRS based on our results is validated in future studies, one could imagine that with
genotyping becoming more frequent, this PRS could be used in clinical practice. Until
then, we will drive the translation from bench-to bedside forward, by testing the prediction
algorithm based on clinical variables in a clinical setting.
5.2 Future perspectives
The field of translational psychiatry is growing rapidly. With results from different
methodologies getting more robust and interpretable, it is only a matter of time until new
concepts will be translated into clinical application. In regards to the results presented in
this thesis, many of the studies have not reached their endpoints.
Specifically, study 3 will be driven forward on two different paths: On one hand the clinical
testing and possible implementation of the algorithm, on the other the strengthening of
the genetic results. The first steps for validation of the algorithm have already been laid
out, with information currently being collected in a prospective manner. If the results
are promising, it may be part of a bigger project of digital health in BD that our group
is currently working on. Regarding genetics, we are proposing to use the ConLiGen to
obtain more data. If this second wave of GWAS provides stronger evidence, the genetic
path could return to the clinic, with a possible implementation of genetic testing before
lithium treatment.
The results of study 4 and study 5 will be followed up in a two-fold way, measuring the same
markers in CSF, as well as in a longitudinal cohort. Here, we will continue to closely work
together with our collaborators, integrating our efforts in regards to samples, financing and
data analysis. The aim will be a better understanding of causal relationships between the
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neurodegenerative and inflammatory pathways and AN, specifically in regards to clinical
variables, specific behaviors, subtypes and outcome.
Finally, in regards to our cell culture project, we are currently planning to start
collaborations with established actors in the field, to finish the project in BD, and possibly
making our samples available to larger consortia. At the same time, a new collection of
fibroblasts of patients with AN is currently being started. Guided by the experiences of
our initial BD study, we are planning this project in a highly collaborative way to increase
our chances of obtaining meaningful results.
5.2.1 A bridge to somewhere. . .
With so many open questions and opportunities, a lot of work still lies ahead. Having
acquired a broad panel of research tools, I will do my best to take part in the building of
future bridges.
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Appendix A
Diagnostic criteria
A.1 Bipolar disorder
DSM-V30
Bipolar I
For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic
episode. The manic episode may have been preceded by and may be followed by hypomanic or
major depressive episodes.
Bipolar II
For a diagnosis of bipolar II disorder, it is necessary to meet the following criteria for a current or
past hypomanic episode and the following criteria for a current or past major depressive episode:
Manic episode
1. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and
abnormally and persistently increased activity or energy, lasting at least 1 week and present
most of the day, nearly every day (or any duration if hospitalization is necessary).
2. During the period of mood disturbance and increased energy or activity, three (or more)
of the following symptoms (four if the mood is only irritable) are present to a significant
degree and represent a noticeable change from usual behavior:
• Inflated self-esteem or grandiosity.
• Decreased need for sleep.
• More talkative than usual or pressure to keep talking.
• Flight of ideas or subjective experience that thoughts are racing.
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• Distractibility.
• Increase in goal-directed activity or psychomotor agitation.
• Excessive involvement in activities that have a high potential for painful consequences.
3. The mood disturbance is sufficiently severe to cause marked impairment in social or
occupational functioning or to necessitate hospitalization to prevent harm to self or others,
or there are psychotic features.
4. The episode is not attributable to the physiological effects of a substance (e.g., a drug of
abuse, a medication, other treatment) or another medical condition.
Hypomanic episode
The differences between a manic and a hypomanic episode are in italic.
1. A distinct period of abnormally and persistently elevated, expansive, or irritable mood and
abnormally and persistently increased activity or energy, lasting at least 4 consecutive days
and present most of the day, nearly every day.
2. cf. Manic episode
3. The episode is associated with an unequivocal change in functioning that is uncharacteristic
of the individual when not symptomatic.
4. The disturbance in mood and the change in functioning are observable by others.
5. The episode is not severe enough to cause marked impairment in social or occupational
functioning or to necessitate hospitalization. If there are psychotic features, the episode is,
by definition, manic.
6. The episode is not attributable to the physiological effects of a substance (e.g., a drug of
abuse, a medication, other treatment) or another medical condition.
Major depressive episode
1. Five (or more) of the following symptoms have been present during the same 2-week
period and represent a change from previous functioning; at least one of the symptoms is
either (1) depressed mood or (2) loss of interest or pleasure. +Depressed mood +Markedly
diminished interest in all or almost all activities +Weight loss or weight gain +Insomnia or
hypersomnia +Psychomotor agitation or retardation +Fatigue or loss of energy +Feelings
of worthlessness or excessive or innapropriate guilt +Diminished ability to think or
concentrate +Recurrent thoughts of death, suicidal ideation or a suicide attempt
2. The symptoms cause clinically significant distress or impairment in social, occupational or
other important areas of functioning.
3. The episode is not attributable to the physiological effects of a substance or another medical
condition.
68
Specifier: With rapid cycling
Presence of at least four mood episodes in the previous 12 months that meet the criteria for
manic, hypomanic, or major depressive episode.
Note: Episodes are demarcated by either partial or full remissions of at least 2 months or a
switch to an episode of the opposite polarity (e.g., major depressive episode to manic episode).
Note: The essential feature of a rapid-cycling bipolar disorder is the occurrence of at least four
mood episodes during the previous 12 months. These episodes can occur in any combination
and order. The episodes must meet both the duration and symptom number criteria for a major
depressive, manic, or hypomanic episode and must be demarcated by either a period of full
remission or a switch to an episode of the opposite polarity. Manic and hypomanic episodes
are counted as being on the same pole. Except for the fact that they occur more frequently,
the episodes that occur in a rapid-cycling pattern are no different from those that occur in a
non-rapid-cycling pattern. Mood episodes that count toward defining a rapid-cycling pattern
exclude those episodes directly caused by a substance (e.g., cocaine, corticosteroids) or another
medical condition.
Specifier: With psychotic features
Delusions or hallucinations are present at any time in the episode. If psychotic features are
present, specify if mood- congruent or mood-incongruent:
When applied to current or most recent manic episode (in bipolar I disorder):
With mood-congruent psychotic features: The content of all delusions and hallucinations
is consistent with the typical manic themes of grandiosity, invulnerability, etc., but may also
include themes of suspiciousness or paranoia, especially with respect to others’ doubts about the
individual’s capacities, accomplishments, and so forth.
With mood-incongruent psychotic features: The content of delusions and hallucinations
does not involve typical manic themes as described above, or the content is a mixture of
mood-incongruent and mood-congruent themes.
When applied to current or most recent major depressive episode (in bipolar I disorder or bipolar
II disorder):
With mood-congruent psychotic features: The content of all delusions and hallucinations
is consistent with the typical depressive themes of personal inadequacy, guilt, disease, death,
nihilism, or deserved punishment.
With mood-incongruent psychotic features: The content of the delusions or hallucinations
does not involve typical depressive themes of personal inadequacy, guilt, disease, death, nihilism,
or deserved punishment, or the content is a mixture of mood-incongruent and mood- congruent
themes.
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ICD-106
F30.0 - Hypomania A disorder characterized by a persistent mild elevation of mood, increased
energy and activity, and usually marked feelings of well-being and both physical and mental
efficiency. Increased sociability, talkativeness, over-familiarity, increased sexual energy, and a
decreased need for sleep are often present but not to the extent that they lead to severe disruption
of work or result in social rejection. Irritability, conceit, and boorish behaviour may take the
place of the more usual euphoric sociability. The disturbances of mood and behaviour are not
accompanied by hallucinations or delusions.
F30.1 - Mania without psychotic symptoms Mood is elevated out of keeping with
the patient’s circumstances and may vary from carefree joviality to almost uncontrollable
excitement. Elation is accompanied by increased energy, resulting in overactivity, pressure of
speech, and a decreased need for sleep. Attention cannot be sustained, and there is often marked
distractibility. Self-esteem is often inflated with grandiose ideas and overconfidence. Loss of
normal social inhibitions may result in behaviour that is reckless, foolhardy, or inappropriate to
the circumstances, and out of character.
F30.2 - Mania with psychotic symptoms In addition to the clinical picture described in
F30.1, delusions (usually grandiose) or hallucinations (usually of voices speaking directly to the
patient) are present, or the excitement, excessive motor activity, and flight of ideas are so extreme
that the subject is incomprehensible or inaccessible to ordinary communication.
F31. - Bipolar affective disorder (BAD) A disorder characterized by two or more episodes in
which the patient’s mood and activity levels are significantly disturbed, this disturbance consisting
on some occasions of an elevation of mood and increased energy and activity (hypomania or
mania) and on others of a lowering of mood and decreased energy and activity (depression).
Repeated episodes of hypomania or mania only are classified as bipolar.
F31.0 - BAD, current episode hypomanic The patient is currently hypomanic, and has had at least
one other affective episode (hypomanic, manic, depressive, or mixed) in the past.
F31.1 - BAD, current episode manic without psychotic symptoms The patient is currently manic,
without psychotic symptoms (as in F30.1), and has had at least one other affective episode (hypomanic,
manic, depressive, or mixed) in the past.
F31.2 - BAD, current episode manic with psychotic symptoms The patient is currently manic,
with psychotic symptoms (as in F30.2), and has had at least one other affective episode (hypomanic,
manic, depressive, or mixed) in the past.
F31.3 - BAD, current episode mild or moderate depression The patient is currently depressed,
as in a depressive episode of either mild or moderate severity (F32.0 or F32.1), and has had at least one
authenticated hypomanic, manic, or mixed affective episode in the past.
F31.4 - BAD, current episode severe depression without psychotic symptoms The patient is
currently depressed, as in severe depressive episode without psychotic symptoms (F32.2), and has had at
least one authenticated hypomanic, manic, or mixed affective episode in the past.
F31.5 - BAD, current episode severe depression with psychotic symptoms The patient is
currently depressed, as in severe depressive episode with psychotic symptoms (F32.3), and has had at
least one authenticated hypomanic, manic, or mixed affective episode in the past.
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F31.6 - BAD, current episode mixed The patient has had at least one authenticated hypomanic,
manic, depressive, or mixed affective episode in the past, and currently exhibits either a mixture or a rapid
alteration of manic and depressive symptoms.
F31.7 - BAD, currently in remission The patient has had at least one authenticated hypomanic,
manic, or mixed affective episode in the past, and at least one other affective episode in addition, but is
not currently suffering from any significant mood disturbance, and has not done so for several months.
F32 - Depressive episode In typical mild, moderate, or severe depressive episodes, the patient
suffers from lowering of mood, reduction of energy, and decrease in activity. Capacity for
enjoyment, interest, and concentration is reduced, and marked tiredness after even minimum effort
is common. Sleep is usually disturbed and appetite diminished. Self-esteem and self-confidence
are almost always reduced and, even in the mild form, some ideas of guilt or worthlessness are often
present. The lowered mood varies little from day to day, is unresponsive to circumstances and
may be accompanied by so-called “somatic” symptoms, such as loss of interest and pleasurable
feelings, waking in the morning several hours before the usual time, depression worst in the
morning, marked psychomotor retardation, agitation, loss of appetite, weight loss, and loss of
libido. Depending upon the number and severity of the symptoms, a depressive episode may be
specified as mild, moderate or severe.
F33 - Recurrent depressive disorder A disorder characterized by repeated episodes of
depression as described for depressive episode (F32.-), without any history of independent episodes
of mood elevation and increased energy (mania). There may, however, be brief episodes of mild
mood elevation and overactivity (hypomania) immediately after a depressive episode, sometimes
precipitated by antidepressant treatment. [. . . ] The first episode may occur at any age from
childhood to old age, the onset may be either acute or insidious, and the duration varies from a
few weeks to many months. The risk that a patient with recurrent depressive disorder will have
an episode of mania never disappears completely, however many depressive episodes have been
experienced. If such an episode does occur, the diagnosis should be changed to bipolar affective
disorder (F31.-).6
A.2 Anorexia Nervosa
DSM-V7
1. Restriction of energy intake relative to requirements, leading to a significantly low
body weight in the context of age, sex, developmental trajectory, and physical health.
Significantly low weight is defined as a weight that is less than minimally normal or, for
children and adolescents, less than that minimally expected.
2. Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with
weight gain, even though at a significantly low weight.
3. Disturbance in the way in which one’s body weight or shape is experienced, undue influence
of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness
of the current low body weight.
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The ICD-10-CM code depends on the subtype. Specify whether:
1. (F50.01) Restricting type: During the last 3 months, the individual has not engaged
in recurrent episodes of binge eating or purging behavior (i.e., self-induced vomiting or the
misuse of laxatives, diuretics, or enemas). This subtype describes presentations in which
weight loss is accomplished primarily through dieting, fasting, and/or excessive exercise.
2. (F50.02) Binge-eating/purging type: During the last 3 months, the individual has
engaged in recurrent episodes of binge eating or purging behavior (i.e., self-induced vomiting
or the misuse of laxatives, diuretics, or enemas).
Specify if:
1. In partial remission: After full criteria for anorexia nervosa were previously met,
Criterion 1 (low body weight) has not been met for a sustained period, but either Criterion
2 (intense fear of gaining weight or becoming fat or behavior that interferes with weight
gain) or Criterion 3 (disturbances in self-perception of weight and shape) is still met.
2. In full remission: After full criteria for anorexia nervosa were previously met, none of
the criteria have been met for a sustained period of time.
Specify current severity: The minimum level of severity is based, for adults, on current body mass
index (BMI) (see below) or, for children and adolescents, on BMI percentile. The ranges below
are derived from World Health Organization categories for thinness in adults; for children and
adolescents, corresponding BMI percentiles should be used. The level of severity may be increased
to reflect clinical symptoms, the degree of functional disability, and the need for supervision.
• Mild: BMI >= 17 kg/m2
• Moderate: BMI 16–16.99 kg/m2
• Severe: BMI 15–15.99 kg/m2
• Extreme: BMI < 15 kg/m2
ICD-106
F50.0 - Anorexia Nervosa A disorder characterized by deliberate weight loss, induced and
sustained by the patient. It occurs most commonly in adolescent girls and young women, but
adolescent boys and young men may also be affected, as may children approaching puberty and
older women up to the menopause. The disorder is associated with a specific psychopathology
whereby a dread of fatness and flabbiness of body contour persists as an intrusive overvalued idea,
and the patients impose a low weight threshold on themselves. There is usually undernutrition
of varying severity with secondary endocrine and metabolic changes and disturbances of bodily
function. The symptoms include restricted dietary choice, excessive exercise, induced vomiting
and purgation, and use of appetite suppressants and diuretics.
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F50.1 - Atypical anorexia nervosa Disorders that fulfil some of the features of anorexia
nervosa but in which the overall clinical picture does not justify that diagnosis. For instance,
one of the key symptoms, such as amenorrhoea or marked dread of being fat, may be absent in
the presence of marked weight loss and weight-reducing behaviour. This diagnosis should not be
made in the presence of known physical disorders associated with weight loss.
73
References
All cited websites were accessed between November 2019 and February 2020 and were still
accessible when the thesis went to print.
1. Cross-Disorder Group of the Psychiatric Genomics Consortium, Wellcome Trust Case-Control
Consortium, Research team, Psychosis Endophenotypes International Consortium & others. Genomic
relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179,
1469–1482 (2019).
2. Ruderfer, D. M. et al. Genomic dissection of bipolar disorder and schizophrenia, including 28
subphenotypes. Cell 173, 1705–1715 (2018).
3. Mitelman, S. A. Transdiagnostic neuroimaging in psychiatry: A review. Psychiatry Research 277,
23–38 (2019).
4. Coleman, J. R. I. et al. Genome-wide gene-environment analyses of major depressive
disorder and reported lifetime traumatic experiences in UK biobank. Molecular Psychiatry (2020)
doi:10.1038/s41380-019-0546-6.
5. Insel, T. R. A bridge to somewhere. Translational psychiatry 1, e2 (2011).
6. World Health Organisation. International Statistical Classification of Diseases and Related Health
Problems (ICD)-10. (1992).
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition.
(2013).
8. Insel, T. Transforming Diagnosis. (2013).
9. National Institute of Mental Health. Research Domain Criteria (RDoC). (2017).
10. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: Etymology and strategic
intentions. American journal of psychiatry 160, 636–645 (2003).
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions
and conceptual framework. Clinical Pharmacology & Therapeutics 69, 89–95 (2001).
12. Nasrallah, H. A. Biomarkers in neuropsychiatric disorders: Translating research to clinical applications.
Biomarkers in Neuropsychiatry 1, 100001 (2019).
13. Flint, J. & Kendler, K. S. The Genetics of Major Depression. Neuron 81, 484–503 (2014).
14. Duncan, L. E., Ostacher, M. & Ballon, J. How genome-wide association studies (gwas) made traditional
candidate gene studies obsolete. Neuropsychopharmacology 44, 1518–1523 (2019).
15. Sullivan, P. F. et al. Psychiatric genomics: An update and an agenda. The American journal of
psychiatry 175, 15–27 (2018).
74
16. Aydin, O., Aydin, P. U. & Arslan, A. Development of neuroimaging-based biomarkers in psychiatry.
in Frontiers in psychiatry 159–195 (Springer Singapore, 2019). doi:10.1007/978-981-32-9721-0_9.
17. Matheson, G. J. et al. Clinical brain pet research must embrace multi-centre collaboration and data
sharing or risk its demise. European journal of nuclear medicine and molecular imaging 1–3 (2019).
18. Yuan, N., Chen, Y., Xia, Y., Dai, J. & Liu, C. Inflammation-related biomarkers in major psychiatric
disorders: A cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Translational
Psychiatry 9, (2019).
19. Teixeira, A. L., Salem, H., Frey, B. N., Barbosa, I. G. & Machado-Vieira, R. Update on bipolar
disorder biomarker candidates. Expert review of molecular diagnostics 16, 1209–1220 (2016).
20. Bai, S. et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive
disorder: A systematic review and meta-analysis of randomised controlled trials. Journal of Neurology,
Neurosurgery & Psychiatry 91, 21–32 (2019).
21. Soliman, M. A., Aboharb, F., Zeltner, N. & Studer, L. Pluripotent stem cells in neuropsychiatric
disorders. Molecular Psychiatry 1–9 (2017) doi:10.1038/mp.2017.40.
22. Takahashi, K. et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined
Factors. Cell 131, 861–872 (2007).
23. Staerk, J. et al. Reprogramming of Human Peripheral Blood Cells to Induced Pluripotent Stem Cells.
Cell Stem Cell 7, 20–24 (2010).
24. Brennand, K. J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature
473, 221–225 (2011).
25. Mertens, J. et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar
disorder. Nature 1–17 (2015) doi:10.1038/nature15526.
26. Stern, S. et al. Neurons derived from patients with bipolar disorder divide into intrinsically different
sub-populations of neurons, predicting the patients’ responsiveness to lithium. Molecular Psychiatry 1–13
(2017) doi:10.1038/mp.2016.260.
27. Hoffman, G. E., Schrode, N., Flaherty, E. & Brennand, K. J. New considerations for hiPSC-based
models of neuropsychiatric disorders. Molecular psychiatry 24, 49–66 (2019).
28. Fromer, M. et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia.
Nature Neuroscience 19, 1442–1453 (2016).
29. Warren, C. R., Jaquish, C. E. & Cowan, C. A. The nextgen genetic association studies consortium: A
foray into in vitro population genetics. Cell stem cell 20, 431–433 (2017).
30. American Psychiatric Association. Bipolar disorders. in Diagnostic and statistical manual of mental
disorders, fifth edition (2013). doi:http://dx.doi.org/10.1176/appi.books.9780890425596.dsm03.
31. Vieta, E. et al. Bipolar disorders. Nature reviews. Disease primers 4, 18008 (2018).
32. Abuse, S. & Mental Health Services Administration. Impact of the dsm-iv to dsm-5 changes on
the national survey on drug use and health [internet]. https://www.ncbi.nlm.nih.gov/books/NBK519697/
(2016).
33. Merikangas, K. R. et al. Prevalence and correlates of bipolar spectrum disorder in the world mental
health survey initiative. Arch.Gen.Psychiatry 68, 241–251 (2011).
34. Rowland, T. A. & Marwaha, S. Epidemiology and risk factors for bipolar disorder. Therapeutic
advances in psychopharmacology 8, 251–269 (2018).
75
35. Lee, S. et al. Rapid-cycling bipolar disorder: Cross-national community study. The British Journal
of Psychiatry 196, 217–225 (2010).
36. Goodwin, F. K. & Jamison, K. R.Manic-depressive illness: Bipolar disorders and recurrent depression.
vol. 1 (Oxford University Press, 2007).
37. Schaffer, A. et al. Epidemiology, neurobiology and pharmacological interventions related to suicide
deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar
Disorders Task Force on Suicide in Bipolar Disorder. The Australian and New Zealand journal of psychiatry
49, 785–802 (2015).
38. Maletic, V. & Raison, C. Integrated Neurobiology of Bipolar Disorder. Frontiers in Psychiatry 5,
(2014).
39. Craddock, N. & Jones, I. Genetics of bipolar disorder. J Med Genet 36, 585–594 (1999).
40. Craddock, N. & Sklar, P. Genetics of bipolar disorder. The Lancet 381, 1654–1662 (2013).
41. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci,
and pleiotropic mechanisms across eight psychiatric disorders. Cell 179, 1469–1482 (2019).
42. Watson, H. J. et al. Genome-wide association study identifies eight risk loci and implicates
metabo-psychiatric origins for anorexia nervosa. Nature genetics 51, 1207–1214 (2019).
43. Seifuddin, F. et al. Meta-analysis of genetic association studies on bipolar disorder. American journal
of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society
of Psychiatric Genetics 159B, 508–18 (2012).
44. Stahl, E. A. et al. Genome-wide association study identifies 30 loci associated with bipolar disorder.
Nature genetics 51, 793–803 (2019).
45. Prata, D. P., Costa-Neves, B., Cosme, G. & Vassos, E. Unravelling the genetic basis of schizophrenia
and bipolar disorder with gwas: A systematic review. Journal of psychiatric research (2019).
46. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108
schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).
47. Green, E. K. et al. Copy number variation in bipolar disorder. Molecular Psychiatry 21, 89–93 (2016).
48. Malhotra, D. & Sebat, J. CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics.
Cell 148, 1223–1241 (2012).
49. Bergen, S. E. et al. Genome-wide association study in a Swedish population yields support for greater
CNV and MHC involvement in schizophrenia compared with bipolar disorder. Molecular Psychiatry 17,
880–886 (2012).
50. Hibar, D. et al. Cortical abnormalities in bipolar disorder: An mri analysis of 6503 individuals from
the enigma bipolar disorder working group. Molecular psychiatry 23, 932–942 (2018).
51. Hibar, D. et al. Subcortical volumetric abnormalities in bipolar disorder. Molecular psychiatry 21,
1710–1716 (2016).
52. Favre, P. et al. Widespread white matter microstructural abnormalities in bipolar disorder: Evidence
from mega-and meta-analyses across 3033 individuals. Neuropsychopharmacology 44, 2285–2293 (2019).
53. Gigante, A. D. et al. Brain glutamate levels measured by magnetic resonance spectroscopy in patients
with bipolar disorder: A meta-analysis. Bipolar disorders 14, 478–487 (2012).
54. Chitty, K. M., Lagopoulos, J., Lee, R. S. C., Hickie, I. B. & Hermens, D. F. A systematic review and
meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder.
76
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
23, 1348–1363 (2013).
55. Pereira, L. P. et al. The relationship between genetic risk variants with brain structure and function
in bipolar disorder: A systematic review of genetic-neuroimaging studies. Neuroscience & Biobehavioral
Reviews 79, 87–109 (2017).
56. Viswanath, B. et al. Cellular models to study bipolar disorder: A systematic review. Journal of
affective disorders 184, 36–50 (2015).
57. Jiang, X. et al. Sodium valproate rescues expression of trank1 in iPSC-derived neural cells that carry
a genetic variant associated with serious mental illness. Molecular psychiatry 24, 613–624 (2019).
58. Harrison, P. J., Colbourne, L. & Harrison, C. H. The neuropathology of bipolar disorder: Systematic
review and meta-analysis. Molecular psychiatry 1–22 (2018).
59. Schmider, J. et al. Combined dexamethasone/corticotropin-releasing hormone test in acute and
remitted manic patients, in acute depression, and in normal controls: I. Biological Psychiatry 38, 797–802
(1995).
60. Murri, M. B. et al. The hpa axis in bipolar disorder: Systematic review and meta-analysis.
Psychoneuroendocrinology 63, 327–342 (2016).
61. Havermans, R., Nicolson, N. A., Berkhof, J. & deVries, M. W. Patterns of salivary cortisol secretion
and responses to daily events in patients with remitted bipolar disorder. Psychoneuroendocrinology 36,
258–265 (2011).
62. Grossman, F. & Potter, W. Z. Catecholamines in depression: A cumulative study of urinary
norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy
volunteers at the nimh. Psychiatry research 87, 21–27 (1999).
63. Frye, M. A. et al. Association between lower serum free t4 and greater mood instability and depression
in lithium-maintained bipolar patients. The American journal of psychiatry 156, 1909–1914 (1999).
64. Modabbernia, A., Taslimi, S., Brietzke, E. & Ashrafi, M. Cytokine alterations in bipolar disorder: A
meta-analysis of 30 studies. Biological psychiatry 74, 15–25 (2013).
65. Munkholm, K., Braüner, J. V., Kessing, L. V. & Vinberg, M. Cytokines in bipolar disorder vs. Healthy
control subjects: A systematic review and meta-analysis. Journal of psychiatric research 47, 1119–1133
(2013).
66. Rowland, T. et al. Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar
disorder: Systematic review and meta-analyses. The British Journal of Psychiatry 213, 514–525 (2018).
67. Tylee, D. S. et al. Genetic correlations among psychiatric and immune-related phenotypes based on
genome-wide association data. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
177, 641–657 (2018).
68. Milhiet, V., Etain, B., Boudebesse, C. & Bellivier, F. Circadian biomarkers, circadian genes and
bipolar disorders. Journal of Physiology-Paris 105, 183–189 (2011).
69. Milhiet, V. et al. Circadian abnormalities as markers of susceptibility in bipolar disorders. Front
Biosci (Schol Ed) 6, 120–137 (2014).
70. Rock, P., Goodwin, G., Harmer, C. & Wulff, K. Daily rest-activity patterns in the bipolar phenotype:
A controlled actigraphy study. Chronobiology international 31, 290–296 (2014).
71. Bae, M. et al. Lifetime experiences of hypomanic symptoms are associated with delayed and irregular
sleep–wake cycle and seasonality in non-clinical adult samples. Comprehensive psychiatry 55, 1111–1115
(2014).
77
72. Jones, S. H., Hare, D. J. & Evershed, K. Actigraphic assessment of circadian activity and sleep patterns
in bipolar disorder. Bipolar disorders 7, 176–186 (2005).
73. Gonzalez, R. The relationship between bipolar disorder and biological rhythms. The Journal of clinical
psychiatry 75, e323–31 (2014).
74. Morris, G. et al. A model of the mitochondrial basis of bipolar disorder. Neuroscience & Biobehavioral
Reviews 74, 1–20 (2017).
75. Cade, J. F. Lithium salts in the treatment of psychotic excitement. The Medical Journal of Australia
II, 349–350 (1949).
76. Joas, E. et al. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder.
The British journal of psychiatry : the journal of mental science 210, 197–202 (2017).
77. Grandjean, E. M. & Aubry, J.-M. Lithium: Updated human knowledge using an evidence-based
approach: Part iii: Clinical safety. CNS drugs 23, 397–418 (2009).
78. Song, J. et al. Suicidal behavior during lithium and valproate treatment: A within-individual 8-year
prospective study of 50,000 patients with bipolar disorder. The American journal of psychiatry 174,
795–802 (2017).
79. Alda, M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Molecular
Psychiatry 1–10 (2015) doi:10.1038/mp.2015.4.
80. Malhi, G. S., Tanious, M., Das, P., Coulston, C. M. & Berk, M. Potential mechanisms of action of
lithium in bipolar disorder: Current understanding. CNS Drugs 27, 135–153 (2013).
81. Malhi, G. S. & Outhred, T. Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances
and Current Understanding. CNS Drugs 30, 931–949 (2016).
82. Caberlotto, L. et al. Differential effects of glycogen synthase kinase 3 (gsk3) inhibition by lithium or
selective inhibitors in the central nervous system. Naunyn-Schmiedeberg’s archives of pharmacology 386,
893–903 (2013).
83. Ward, M. E., Musa, M. N. & Bailey, L. Clinical pharmacokinetics of lithium. Journal of clinical
pharmacology 34, 280–285 (1994).
84. Diamond, J. M., Ehrlich, B. E., Morawski, S. G., Santa Ana, C. A. & Dordtran, J. S. Lithium
absorption in tight and leaky segments of intestine. The Journal of membrane biology 72, 153–159 (1983).
85. Grandjean, E. M. & Aubry, J.-M. Lithium: Updated human knowledge using an evidence-based
approach. CNS drugs 23, 225–240 (2009).
86. Soares, J. C., Boada, F. & Keshavan, M. S. Brain lithium measurements with 7Li magnetic resonance
spectroscopy (mrs): A literature review. European Neuropsychopharmacology 10, 151–158 (2000).
87. Smith, F. E. et al. 3D 7 li magnetic resonance imaging of brain lithium distribution in bipolar disorder.
Molecular psychiatry 23, 2184–2191 (2018).
88. Koomans, H. A., Boer, W. H. & Mees, E. J. D. Evaluation of lithium clearance as a marker of proximal
tubule sodium handling. Kidney international 36, (1989).
89. Mason, R., McQueen, E., Keary, P. & James, N. M. Pharmacokinetics of lithium: Elimination
half-time, renal clearance and apparent volume of distribution in schizophrenia. Clinical pharmacokinetics
3, 241–246 (1978).
90. Thornhill, D. & Field, S. Distribution of lithium elimination rates in a selected population of psychiatric
patients. European journal of clinical pharmacology 21, 351–354 (1982).
78
91. Hewick, D. S., Newbury, P., Hopwood, S., Naylor, G. & Moody, J. Age as a factor affecting lithium
therapy. British journal of clinical pharmacology 4, 201–205 (1977).
92. Reiss, R. A. et al. Lithium pharmacokinetics in the obese. Clinical Pharmacology & Therapeutics 55,
392–398 (1994).
93. Goodnick, P. J., Fieve, R. R., Meltzer, H. L. & Dunner, D. L. Lithium elimination half-life and
duration of therapy. Clinical Pharmacology & Therapeutics 29, 47–50 (1981).
94. Oedegaard, K. J. et al. The pharmacogenomics of bipolar disorder study (pgbd): Identification of
genes for lithium response in a prospective sample. BMC psychiatry 16, 129 (2016).
95. Fass. Lithionit. https://www.fass.se/LIF/product?userType=0&nplId=19971114000058.
96. Treasure, J. et al. Anorexia nervosa. Nature reviews. Disease primers 1, 15074 (2015).
97. Sattler, F. A., Eickmeyer, S. & Eisenkolb, J. Body image disturbance in children and adolescents with
anorexia nervosa and bulimia nervosa: A systematic review. Eating and weight disorders : EWD (2019)
doi:10.1007/s40519-019-00725-5.
98. American Psychiatric Association. Anorexia Nervosa. in Diagnostic and statistical manual of mental
disorders, fifth edition (2013). doi:http://dx.doi.org/10.1176/appi.books.9780890425596.dsm04.
99. Støving, R. K., Andries, A., Brixen, K., Bilenberg, N. & Hørder, K. Gender differences in outcome of
eating disorders: A retrospective cohort study. Psychiatry research 186, 362–366 (2011).
100. Walsh, B. T. The enigmatic persistence of anorexia nervosa. American Journal of Psychiatry 170,
477–484 (2013).
101. Frank, G. K. What causes eating disorders, and what do they cause? Biological Psychiatry 77,
602–603 (2015).
102. Zipfel, S., Giel, K. E., Bulik, C. M., Hay, P. & Schmidt, U. Anorexia nervosa: Aetiology, assessment,
and treatment. The lancet psychiatry 2, 1099–1111 (2015).
103. Swanson, S. A. et al. Assessing eating disorder symptoms in adolescence: Is there a role for multiple
informants? International Journal of Eating Disorders 47, 475–482 (2014).
104. Stice, E., Marti, C. N., Shaw, H. & Jaconis, M. An 8-year longitudinal study of the natural history
of threshold, subthreshold, and partial eating disorders from a community sample of adolescents. Journal
of Abnormal Psychology 118, 587–597 (2009).
105. Keski-Rahkonen, A. et al. Epidemiology and course of anorexia nervosa in the community. The
American journal of psychiatry 164, 1259–1265 (2007).
106. Wade, T. D., Bergin, J. L., Tiggemann, M., Bulik, C. M. & Fairburn, C. G. Prevalence and long-term
course of lifetime eating disorders in an adult australian twin cohort. Australian & New Zealand Journal
of Psychiatry 40, 121–128 (2006).
107. Bulik, C. M. et al. Prevalence, heritability, and prospective risk factors for anorexia nervosa. Archives
of General Psychiatry 63, 305 (2006).
108. Raevuori, A. et al. Epidemiology of anorexia nervosa in men: A nationwide study of finnish twins.
PloS one 4, e4402 (2009).
109. Son, G. E. van, Hoeken, D. van, Bartelds, A. I. M., Furth, E. F. van & Hoek, H. W. Time trends
in the incidence of eating disorders: A primary care study in the netherlands. International Journal of
Eating Disorders 39, 565–569 (2006).
79
110. Steinhausen, H.-C. & Jensen, C. M. Time trends in lifetime incidence rates of first-time diagnosed
anorexia nervosa and bulimia nervosa across 16 years in a danish nationwide psychiatric registry study.
International Journal of Eating Disorders 48, 845–850 (2015).
111. Javaras, K. N. et al. Sex- and age-specific incidence of healthcare-register-recorded eating disorders
in the complete swedish 1979-2001 birth cohort. International Journal of Eating Disorders 48, 1070–1081
(2015).
112. Yao, S. et al. Familial liability for eating disorders and suicide attempts. JAMA Psychiatry 73, 284
(2016).
113. Swanson, S. A. Prevalence and correlates of eating disorders in adolescents. Archives of General
Psychiatry 68, 714 (2011).
114. Fernandez-Aranda, F. et al. Symptom profile of major depressive disorder in women with eating
disorders. Australian & New Zealand Journal of Psychiatry 41, 24–31 (2007).
115. Swinbourne, J. M. & Touyz, S. W. The co-morbidity of eating disorders and anxiety disorders: A
review. European Eating Disorders Review 15, 253–274 (2007).
116. Godart, N. T., Flament, M. F., Perdereau, F. & Jeammet, P. Comorbidity between eating disorders
and anxiety disorders: A review. International Journal of Eating Disorders 32, 253–270 (2002).
117. Kaye, W. H., Bulik, C. M., Thornton, L., Barbarich, N. & and, K. M. Comorbidity of anxiety
disorders with anorexia and bulimia nervosa. American Journal of Psychiatry 161, 2215–2221 (2004).
118. Salbach-Andrae, H. et al. Psychiatric comorbidities among female adolescents with anorexia nervosa.
Child Psychiatry and Human Development 39, 261–272 (2007).
119. Cederlöf, M. et al. Etiological overlap between obsessive-compulsive disorder and anorexia nervosa:
A longitudinal cohort, multigenerational family and twin study. World Psychiatry 14, 333–338 (2015).
120. Root, T. L. et al. Substance use disorders in women with anorexia nervosa. International Journal of
Eating Disorders NA–NA (2009) doi:10.1002/eat.20670.
121. Baron-Cohen, S. et al. Do girls with anorexia nervosa have elevated autistic traits? Molecular autism
4, 24 (2013).
122. Koch, S. V. et al. Autism spectrum disorder in individuals with anorexia nervosa and in their first-
and second-degree relatives: Danish nationwide register-based cohort-study. British Journal of Psychiatry
206, 401–407 (2015).
123. Chesney, E., Goodwin, G. M. & Fazel, S. Risks of all-cause and suicide mortality in mental disorders:
A meta-review. World Psychiatry 13, 153–160 (2014).
124. Arcelus, J. Mortality rates in patients with anorexia nervosa and other eating disorders. Archives of
General Psychiatry 68, 724 (2011).
125. Eddy, K. T. et al. Recovery from anorexia nervosa and bulimia nervosa at 22-year follow-up. The
Journal of Clinical Psychiatry 78, 184–189 (2016).
126. Schaumberg, K. et al. The science behind the academy for eating disorders’ nine truths about eating
disorders. European eating disorders review : the journal of the Eating Disorders Association 25, 432–450
(2017).
127. Couturier, J. & Lock, J. What is recovery in adolescent anorexia nervosa? International Journal of
Eating Disorders 39, 550–555 (2006).
128. Ahren-Moonga, J., Silverwood, R., Klinteberg, B. a. & Koupil, I. Association of higher parental
and grandparental education and higher school grades with risk of hospitalization for eating disorders
80
in females: The uppsala birth cohort multigenerational study. American Journal of Epidemiology 170,
566–575 (2009).
129. Lang, K., Lopez, C., Stahl, D., Tchanturia, K. & Treasure, J. Central coherence in eating disorders:
An updated systematic review and meta-analysis. The World Journal of Biological Psychiatry 15, 586–598
(2014).
130. Lavender, J. M. et al. Dimensions of emotion dysregulation in anorexia nervosa and bulimia nervosa:
A conceptual review of the empirical literature. Clinical Psychology Review 40, 111–122 (2015).
131. Wu, M., Hartmann, M., Skunde, M., Herzog, W. & Friederich, H.-C. Inhibitory control in bulimic-type
eating disorders: A systematic review and meta-analysis. PLoS ONE 8, e83412 (2013).
132. Limburg, K., Watson, H. J., Hagger, M. S. & Egan, S. J. The relationship between perfectionism and
psychopathology: A meta-analysis. Journal of Clinical Psychology 73, 1301–1326 (2016).
133. O’Hara, C. B., Campbell, I. C. & Schmidt, U. A reward-centred model of anorexia nervosa: A focussed
narrative review of the neurological and psychophysiological literature. Neuroscience & Biobehavioral
Reviews 52, 131–152 (2015).
134. Karpowicz, E., Skärsäter, I. & Nevonen, L. Self-esteem in patients treated for anorexia nervosa.
International Journal of Mental Health Nursing 18, 318–325 (2009).
135. Steinhausen, H.-C., Jakobsen, H., Helenius, D., Munk-Jørgensen, P. & Strober, M. A nation-wide
study of the family aggregation and risk factors in anorexia nervosa over three generations. International
Journal of Eating Disorders 48, 1–8 (2014).
136. Strober, M. Controlled family study of anorexia nervosa and bulimia nervosa: Evidence of shared
liability and transmission of partial syndromes. American Journal of Psychiatry 157, 393–401 (2000).
137. Klump, K. L., Miller, K. B., Keel, P. K., McGue, M. & Iacono, W. G. Genetic and environmental
influences on anorexia nervosa syndromes in a populationbased twin sample. Psychological Medicine 31,
737–740 (2001).
138. Bulik, C. M. et al. Understanding the relation between anorexia nervosa and bulimia nervosa in a
swedish national twin sample. Biological Psychiatry 67, 71–77 (2010).
139. Bulik, C., Yilmaz, Z. & HArdaway, A. Genetics and epigenetics of eating disorders. Advances in
Genomics and Genetics 131 (2015) doi:10.2147/agg.s55776.
140. Duncan, L. et al. Significant locus and metabolic genetic correlations revealed in genome-wide
association study of anorexia nervosa. American journal of psychiatry 174, 850–858 (2017).
141. Stelzer, G. et al. The genecards suite: From gene data mining to disease genome sequence analyses.
Current protocols in bioinformatics 54, 1–30 (2016).
142. Rathjen, T. et al. Regulation of body weight and energy homeostasis by neuronal cell adhesion
molecule 1. Nature Neuroscience 20, 1096–1103 (2017).
143. Bacon, C. et al. Brain-specific foxp1 deletion impairs neuronal development and causes autistic-like
behaviour. Molecular psychiatry 20, 632–639 (2015).
144. Sild, M. & Booij, L. Histone deacetylase 4 (HDAC4): A new player in anorexia nervosa? Molecular
Psychiatry 24, 1425–1434 (2019).
145. Van den Eynde, F. et al. Structural magnetic resonance imaging in eating disorders: A systematic
review of voxel-based morphometry studies. European eating disorders review : the journal of the Eating
Disorders Association 20, 94–105 (2012).
81
146. Titova, O. E., Hjorth, O. C., Schiöth, H. B. & Brooks, S. J. Anorexia nervosa is linked to reduced
brain structure in reward and somatosensory regions: A meta-analysis of vbm studies. BMC psychiatry
13, 110 (2013).
147. Frank, G. K. W. Recent advances in neuroimaging to model eating disorder neurobiology. Current
psychiatry reports 17, 559 (2015).
148. King, J. A., Frank, G. K. W., Thompson, P. M. & Ehrlich, S. Structural neuroimaging of anorexia
nervosa: Future directions in the quest for mechanisms underlying dynamic alterations. Biological
psychiatry 83, 224–234 (2018).
149. Seitz, J., Herpertz-Dahlmann, B. & Konrad, K. Brain morphological changes in adolescent and adult
patients with anorexia nervosa. Journal of neural transmission (Vienna, Austria : 1996) 123, 949–959
(2016).
150. Martin Monzon, B., Hay, P., Foroughi, N. & Touyz, S. White matter alterations in anorexia nervosa:
A systematic review of diffusion tensor imaging studies. World journal of psychiatry 6, 177–186 (2016).
151. King, J. A. et al. Global cortical thinning in acute anorexia nervosa normalizes following long-term
weight restoration. Biological psychiatry 77, 624–632 (2015).
152. Roberto, C. A. et al. Brain tissue volume changes following weight gain in adults with anorexia
nervosa. The International journal of eating disorders 44, 406–411 (2011).
153. Bernardoni, F. et al. Weight restoration therapy rapidly reverses cortical thinning in anorexia nervosa:
A longitudinal study. NeuroImage 130, 214–222 (2016).
154. Nickel, K. et al. White matter abnormalities in the corpus callosum in acute and recovered anorexia
nervosa patients-a diffusion tensor imaging study. Frontiers in psychiatry 10, 490 (2019).
155. Walton, E. et al. Exploration of shared genetic architecture between subcortical brain volumes and
anorexia nervosa. Molecular Neurobiology 56, 5146–5156 (2018).
156. Steward, T., Menchon, J. M., Jiménez-Murcia, S., Soriano-Mas, C. & Fernandez-Aranda, F.
Neural network alterations across eating disorders: A narrative review of fMRI studies. Current
Neuropharmacology 16, 1150–1163 (2018).
157. Lawson, E. A. & Klibanski, A. Endocrine abnormalities in anorexia nervosa. Nature clinical practice.
Endocrinology & metabolism 4, 407–414 (2008).
158. Misra, M. et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa
and effects on bone metabolism. The Journal of Clinical Endocrinology & Metabolism 89, 4972–4980
(2004).
159. Misra, M. et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia
nervosa and effects on bone metabolism. The Journal of Clinical Endocrinology & Metabolism 88,
5615–5623 (2003).
160. Croxson, M. S. & Ibbertson, H. K. Low serum triiodothyronine (t3) and hypothyroidism in anorexia
nervosa. The Journal of Clinical Endocrinology & Metabolism 44, 167–174 (1977).
161. Grinspoon, S. et al. Serum leptin levels in women with anorexia nervosa. The Journal of Clinical
Endocrinology & Metabolism 81, 3861–3863 (1996).
162. Misra, M. et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy
adolescents. American Journal of Physiology-Endocrinology and Metabolism 289, E373–E381 (2005).
163. Steinman, J. & Shibli-Rahhal, A. Anorexia nervosa and osteoporosis: Pathophysiology and treatment.
Journal of bone metabolism 26, 133–143 (2019).
82
164. Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation
to sickness and depression: When the immune system subjugates the brain. Nature reviews neuroscience
9, 46 (2008).
165. Gautron, L. & Layé, S. Neurobiology of inflammation-associated anorexia. Frontiers in neuroscience
3, 3 (2010).
166. Netea, M. G. et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin
resistance. Nature medicine 12, 650 (2006).
167. Heredia, F. P. de, Gómez-Martı’nez, S. & Marcos, A. Obesity, inflammation and the immune system.
Proceedings of the Nutrition Society 71, 332–338 (2012).
168. Gibson, D. & Mehler, P. S. Anorexia nervosa and the immune system—a narrative review. Journal
of clinical medicine 8, 1915 (2019).
169. Pape, K., Tamouza, R., Leboyer, M. & Zipp, F. Immunoneuropsychiatry—novel perspectives on
brain disorders. Nature Reviews Neurology 1 (2019).
170. Hedman, A. et al. Bidirectional relationship between eating disorders and autoimmune diseases.
Journal of Child Psychology and Psychiatry 60, 803–812 (2019).
171. Fetissov, S. O. & Hökfelt, T. On the origin of eating disorders: Altered signaling between gut
microbiota, adaptive immunity and the brain melanocortin system regulating feeding behavior. Current
Opinion in Pharmacology 48, 82–91 (2019).
172. Dalton, B. et al. Ameta-analysis of cytokine concentrations in eating disorders. Journal of psychiatric
research 103, 252–264 (2018).
173. Negraes, P. D. et al. Modeling anorexia nervosa: Transcriptional insights from human iPSC-derived
neurons. Translational psychiatry 7, e1060 (2017).
174. Schalla, M. A. & Stengel, A. Activity based anorexia as an animal model for anorexia nervosaA
systematic review. Frontiers in Nutrition 6, (2019).
175. Siegfried, Z., Berry, E. M., Hao, S. & Avraham, Y. Animal models in the investigation of anorexia.
Physiology & Behavior 79, 39–45 (2003).
176. Nilsson, I. A. The anx/anx mouse–a valuable resource in anorexia nervosa research. Frontiers in
neuroscience 13, 59 (2019).
177. Maltais, L. J., Lane, P. W. & Beamer, W. G. Anorexia, a recessive mutation causing starvation in
preweanling mice. Journal of Heredity 75, 468–472 (1984).
178. Steinhausen, H.-C. Outcome of eating disorders. Child and Adolescent Psychiatric Clinics of North
America 18, 225–242 (2009).
179. Claudino, A. M. et al. Antidepressants for anorexia nervosa. Cochrane Database of Systematic
Reviews (2006) doi:10.1002/14651858.cd004365.pub2.
180. Vos, J. de et al. Meta analysis on the efficacy of pharmacotherapy versus placebo on anorexia nervosa.
Journal of Eating Disorders 2, (2014).
181. McElroy, S. L. et al. Prevalence and correlates of DSM-5 eating disorders in patients with bipolar
disorder. Journal of Affective Disorders 191, 216–221 (2016).
182. Tseng, M.-C. M., Chang, C.-H., Chen, K.-Y., Liao, S.-C. & Chen, H.-C. Prevalence and correlates of
bipolar disorders in patients with eating disorders. Journal of Affective Disorders 190, 599–606 (2016).
183. McElroy, S. L. et al. Prevalence and correlates of eating disorders in 875 patients with bipolar
disorder. Journal of Affective Disorders 128, 191–198 (2011).
83
184. Crow, S. et al. Factor analysis of the eating disorder diagnostic scale in individuals with bipolar
disorder. Eating Behaviors 33, 30–33 (2019).
185. McElroy, S. L., Kotwal, R., Keck, P. E. & Akiskal, H. S. Comorbidity of bipolar and eating disorders:
Distinct or related disorders with shared dysregulations? Journal of Affective Disorders 86, 107–127
(2005).
186. McAulay, C., Hay, P., Mond, J. & Touyz, S. Eating disorders, bipolar disorders and other mood
disorders: Complex and under-researched relationships. Journal of Eating Disorders 7, (2019).
187. Chen, Y., Bidwell, L. C. & Norton, D. Trait vs. State markers for schizophrenia: Identification and
characterization through visual processes. Current Psychiatry Reviews 2, 431–438 (2006).
188. Scott, J. et al. An examination of the quality and performance of the alda scale for classifying lithium
response phenotypes. Bipolar disorders (2019).
189. Hällström, T., Damström Thakker, K., Forsell, Y., Lundberg, I. & Tinghög, P. The part study:
A population based study of mental health in the stockholm county: Study design phase l (1998-2000).
Stockhom, Sweden: The PART Study Group (2003).
190. Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania: Reliability,
validity and sensitivity. The British journal of psychiatry : the journal of mental science 133, 429–435
(1978).
191. First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. User’s guide for the structured clinical
interview for dsm-iv axis i disorders scid-i: Clinician version. (American Psychiatric Pub, 1997).
192. Thornton, L. M. et al. The anorexia nervosa genetics initiative (angi): Overview and methods.
Contemporary clinical trials 74, 61–69 (2018).
193. Bixo, L., Cunningham, J. L., Ekselius, L., Öster, C. & Ramklint, M. ‘Sick and tired’: Patients
reported reasons for not participating in clinical psychiatric research. Health Expectations (2019)
doi:10.1111/hex.12977.
194. Sinnwell, J. & Schaid, D. Haplo.stats: Statistical analysis of haplotypes with traits and covariates
when linkage phase is ambiguous. (2016).
195. Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage
analyses. American journal of human genetics 81, 559–575 (2007).
196. Coleman, J. R. I. et al. Quality control, imputation and analysis of genome-wide genotyping data
from the illumina humancoreexome microarray. Briefings in functional genomics 15, 298–304 (2016).
197. International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299–1320
(2005).
198. Dudbridge, F. & Gusnanto, A. Estimation of significance thresholds for genomewide association
scans. Genetic epidemiology 32, 227–234 (2008).
199. International HapMap Consortium. Integrating common and rare genetic variation in diverse human
populations. Nature 467, 52–58 (2010).
200. 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526,
68–74 (2015).
201. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for
the next generation of genome-wide association studies. PLoS genetics 5, e1000529 (2009).
202. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized gene-set analysis
of gwas data. PLoS computational biology 11, e1004219 (2015).
84
203. Thomas, P. D. et al. PANTHER: A library of protein families and subfamilies indexed by function.
Genome research 13, 2129–2141 (2003).
204. Watanabe, K., Taskesen, E., Bochoven, A. van & Posthuma, D. Functional mapping and annotation
of genetic associations with fuma. Nature communications 8, 1826 (2017).
205. Buonocore, M. H. & Maddock, R. J. Magnetic resonance spectroscopy of the brain: A review of
physical principles and technical methods. Reviews in the neurosciences 26, 609–632 (2015).
206. Li, C.-T., Yang, K.-C. & Lin, W.-C. Glutamatergic dysfunction and glutamatergic compounds for
major psychiatric disorders: Evidence from clinical neuroimaging studies. Frontiers in psychiatry 9, 767
(2018).
207. Ramadan, S., Lin, A. & Stanwell, P. Glutamate and glutamine: A review of in vivo mrs in the human
brain. NMR in biomedicine 26, 1630–1646 (2013).
208. Hancu, I. & Port, J. The case of the missing glutamine. NMR in biomedicine 24, 529–535 (2011).
209. Hurd, R. et al. Measurement of brain glutamate using te-averaged press at 3T. Magnetic Resonance
in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine 51,
435–440 (2004).
210. Port, J. D., Unal, S. S., Mrazek, D. A. & Marcus, S. M. Metabolic alterations in medication-free
patients with bipolar disorder: A 3T csf-corrected magnetic resonance spectroscopic imaging study.
Psychiatry research 162, 113–121 (2008).
211. OLINK proteomics. PEA: An enabling technology for highmultiplex protein biomarker discovery.
https://www.olink.com/content/uploads/2017/12/1074-v1.0-PEA-White-paper_final.pdf (2017).
212. OLINK proteomics. Data normalization and standardization. https://www.olink.com/content/
uploads/2018/05/Data-normalization-and-standardization_v1.0.pdf (2018).
213. OLINK proteomics. Measuring protein biomarkers with olink — technical comparisons and orthogonal
validation. https://www.olink.com/content/uploads/2019/06/Olink-technical-comparisons-and-orthogonal-
validation-v1.0.pdf (2019).
214. Vangipuram, M., Ting, D., Kim, S., Diaz, R. & Schüle, B. Skin punch biopsy explant culture for
derivation of primary human fibroblasts. JoVE (Journal of Visualized Experiments) e3779 (2013).
215. Diecke, S. et al. Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free
induction of pluripotency. Scientific Reports 5, (2015).
216. Ly, A., Etz, A., Marsman, M. &Wagenmakers, E.-J. Replication bayes factors from evidence updating.
Behavior research methods 51, 2498–2508 (2019).
217. Simonsohn, U. Small telescopes: Detectability and the evaluation of replication results. Psychological
science 26, 559–569 (2015).
218. Dumas-Mallet, E., Button, K. S., Boraud, T., Gonon, F. & Munafò, M. R. Low statistical power
in biomedical science: A review of three human research domains. Royal Society open science 4, 160254
(2017).
219. Matheson, G. J. Reliability, replicability and reproducibility in pet imaging. (Karolinska Institutet,
2018).
220. Probabilistic World. Frequentist and bayesian approaches in statistics. https://www.
probabilisticworld.com/frequentist-bayesian-approaches-inferential-statistics/ (2016).
221. McElreath, R. Statistical rethinking: A bayesian course with examples in r and stan. (Chapman;
Hall/CRC, 2018).
85
222. Kass, R. E. & Raftery, A. E. Bayes factors. Journal of the American Statistical Association 90,
773–795 (1995).
223. Jamil, T. et al. Default ‘gunel and dickey’ bayes factors for contingency tables. Behavior Research
Methods 49, 638–652 (2017).
224. JASP Team. JASP (Version 0.11.1)[Computer software]. (2019).
225. UCLA: Statistical Consulting Group. Introduction to linear mixed models. https://stats.idre.ucla.edu/
other/mult-pkg/introduction-to-linear-mixed-models/ (2020).
226. McElreath, R. Multilevel regression as default. https://elevanth.org/blog/2017/08/24/
multilevel-regression-as-default/ (2017).
227. Hajduk, G. K. Introduction to linear mixed models. https://ourcodingclub.github.io/2017/03/15/
mixed-models.html/ (2017).
228. Gelman, A. & Hill, J. Data analysis using regression and multilevel/hierarchical models. (Cambridge
University Press, 2007).
229. Lyons, M. Generalised additive models (gams): An introduction. http://environmentalcomputing.
net/intro-to-gams/ (2018).
230. Pedersen, E. J., Miller, D. L., Simpson, G. L. & Ross, N. Hierarchical generalized additive models:
An introduction with mgcv. PeerJ Preprints 6, e27320v1 (2018).
231. Flom, P. An introduction to quantile regression. https://towardsdatascience.com/an-introduction-to-
quantile-regression-eca5e3e2036a (2018).
232. Koenker, R. Quantile regression in r: A vignette. (2019).
233. Baum, C. F. Quantile regression (ec 823: Applied econometrics). http://fmwww.bc.edu/EC-C/
S2013/823/EC823.S2013.nn04.slides.pdf (2013).
234. Koenker, R. Quantreg: Quantile regression. (2019).
235. Manning, B. D. & Toker, A. AKT/pkb signaling: Navigating the network. Cell 169, 381–405 (2017).
236. Howell, K. R. & Law, A. J. Neurodevelopmental concepts of schizophrenia in the genome-wide
association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental
programming during development. Schizophrenia Research (2019).
237. Freyberg, Z., Ferrando, S. J. & Javitch, J. A. Roles of the akt/gsk-3 and wnt signaling pathways in
schizophrenia and antipsychotic drug action. American Journal of Psychiatry 167, 388–396 (2009).
238. Toyota, T., Yamada, K., Detera-Wadleigh, S. D. & Yoshikawa, T. Analysis of a cluster of
polymorphisms in akt1 gene in bipolar pedigrees: A family-based association study. Neuroscience letters
339, 5–8 (2003).
239. Karege, F. et al. Association of akt1 gene variants and protein expression in both schizophrenia and
bipolar disorder. Genes, Brain and Behavior 9, 503–511 (2010).
240. Karege, F. et al. Genetic overlap between schizophrenia and bipolar disorder: A study with akt1
gene variants and clinical phenotypes. Schizophrenia research 135, 8–14 (2012).
241. Disorder, B., Psychiatric Genomics Consortium. Electronic address: douglas.ruderfer@vanderbilt.edu,
S. W. G. of the, Disorder, B. & Psychiatric Genomics Consortium, S. W. G. of the. Genomic dissection
of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173, 1705–1715.e16 (2018).
242. Lau, A. & Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Archiv
: European journal of physiology 460, 525–542 (2010).
86
243. McCullumsmith, R. E. et al. Decreased nr1, nr2a, and sap102 transcript expression in the
hippocampus in bipolar disorder. Brain research 1127, 108–118 (2007).
244. Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E. & Meador-Woodruff, J. H.
Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 32,
1888–1902 (2007).
245. Beneyto, M. & Meador-Woodruff, J. H. Lamina-specific abnormalities of nmda receptor-associated
postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 33,
2175–2186 (2008).
246. Rao, J. S., Harry, G. J., Rapoport, S. I. & Kim, H. W. Increased excitotoxicity and neuroinflammatory
markers in postmortem frontal cortex from bipolar disorder patients. Molecular psychiatry 15, 384–392
(2010).
247. Rathje, M. et al. Genetic variants in the bipolar disorder risk locus syne1 that affect cpg2 expression
and protein function. Molecular psychiatry (2019) doi:10.1038/s41380-018-0314-z.
248. Luykx, J. et al. Region and state specific glutamate downregulation in major depressive disorder: A
meta-analysis of 1H-mrs findings. Neuroscience & Biobehavioral Reviews 36, 198–205 (2012).
249. Arnone, D., Mumuni, A. N., Jauhar, S., Condon, B. & Cavanagh, J. Indirect evidence of selective glial
involvement in glutamate-based mechanisms of mood regulation in depression: Meta-analysis of absolute
prefrontal neuro-metabolic concentrations. European Neuropsychopharmacology 25, 1109–1117 (2015).
250. Wirth, C. et al. DTNBP1 (dysbindin) gene variants: In vivo evidence for effects on hippocampal
glutamate status. Current pharmaceutical biotechnology 13, 1513–1521 (2012).
251. Rogdaki, M. et al. Glutamatergic function in a genetic high-risk group for psychosis: A
proton magnetic resonance spectroscopy study in individuals with 22q11. 2 deletion. European
Neuropsychopharmacology (2019).
252. Legind, C. S. et al. Heritability of cerebral glutamate levels and their association with schizophrenia
spectrum disorders: A 1 [h]-spectroscopy twin study. Neuropsychopharmacology 44, 581 (2019).
253. Soeiro-de-Souza, M. G. et al. Bcl-2 rs956572 polymorphism is associated with increased anterior
cingulate cortical glutamate in euthymic bipolar i disorder. Neuropsychopharmacology 38, 468 (2013).
254. Gruber, O. et al. Association of the brain-derived neurotrophic factor val66met polymorphism with
magnetic resonance spectroscopic markers in the human hippocampus: In vivo evidence for effects on the
glutamate system. European archives of psychiatry and clinical neuroscience 262, 23–31 (2012).
255. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: From adhesion molecules to signalling regulators.
Nature reviews Molecular cell biology 4, 33 (2003).
256. Johnson, P. & Ruffell, B. CD44 and its role in inflammation and inflammatory diseases. Inflammation
& Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 8, 208–220 (2009).
257. Dzwonek, J. & Wilczynski, G. M. CD44: Molecular interactions, signaling and functions in the
nervous system. Frontiers in cellular neuroscience 9, 175 (2015).
258. Liu, Y. et al. CD44 expression identifies astrocyte-restricted precursor cells. Developmental biology
276, 31–46 (2004).
259. Matzke, A. et al. Haploinsufficiency of c-met in cd44-/- mice identifies a collaboration of cd44 and
c-met in vivo. Molecular and cellular biology 27, 8797–8806 (2007).
87
260. Michael, N., Erfurth, A. & Pfleiderer, B. Elevated metabolites within dorsolateral prefrontal cortex
in rapid cycling bipolar disorder. Psychiatry Research: Neuroimaging 172, 78–81 (2009).
261. Charles, B. Population pharmacokinetics: An overview. Aust Prescr 37, 210–3 (2014).
262. Ette, E. I. & Williams, P. J. Population pharmacokinetics ii: Estimation methods. The Annals of
pharmacotherapy 38, 1907–1915 (2004).
263. Serra-Juhe, C. et al. Novel genes involved in severe early-onset obesity revealed by rare copy number
and sequence variants. PLoS genetics 13, e1006657 (2017).
264. Barbitoff, Y. et al. Identification of novel candidate markers of type 2 diabetes and obesity in russia
by exome sequencing with a limited sample size. Genes 9, 415 (2018).
265. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density
imputation and islet-specific epigenome maps. Nature genetics 50, 1505 (2018).
266. Kichaev, G. et al. Leveraging polygenic functional enrichment to improve gwas power. American
journal of human genetics 104, 65–75 (2019).
267. Hübel, C. et al. Genomics of body fat percentage may contribute to sex bias in anorexia nervosa.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the
International Society of Psychiatric Genetics 180, 428–438 (2019).
268. Chang, W., Cheng, J., Allaire, J., Xie, Y. & McPherson, J. Shiny: Web application framework for r.
(2019).
269. Masters, C. et al. Alzheimer’s disease. Nature reviews Disease primers 1, 794 (2015).
270. Bos, M. A. van den, Geevasinga, N., Higashihara, M., Menon, P. & Vucic, S. Pathophysiology
and diagnosis of als: Insights from advances in neurophysiological techniques. International Journal of
Molecular Sciences 20, 2818 (2019).
271. Poewe, W. et al. Parkinson disease. Nature reviews Disease primers 3, 17013 (2017).
272. Friese, M. A., Schattling, B. & Fugger, L. Mechanisms of neurodegeneration and axonal dysfunction
in multiple sclerosis. Nature reviews. Neurology 10, 225–238 (2014).
273. Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol
Neurosurg Psychiatry jnnp–2018 (2019).
274. Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nature reviews. Neurology
14, 577–589 (2018).
275. Teunissen, C. E. & Khalil, M. Neurofilaments as biomarkers in multiple sclerosis. Multiple sclerosis
(Houndmills, Basingstoke, England) 18, 552–556 (2012).
276. Kuhle, J. et al. A comparative study of csf neurofilament light and heavy chain protein in ms.
Multiple Sclerosis Journal 19, 1597–1603 (2013).
277. Mattsson, N., Andreasson, U., Zetterberg, H. & Blennow, K. Association of plasma neurofilament
light with neurodegeneration in patients with alzheimer disease. JAMA neurology 74, 557–566 (2017).
278. Alcolea, D. et al. CSF sAPPβ, ykl-40, and neurofilament light in frontotemporal lobar degeneration.
Neurology 89, 178–188 (2017).
279. Shahim, P. et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain
injury. Scientific reports 6, 36791 (2016).
280. Jakobsson, J. et al. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of
bipolar disorder patients. Neuropsychopharmacology 39, 2349 (2014).
88
281. Disanto, G. et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Annals of neurology 81, 857–870 (2017).
282. Shahim, P., Zetterberg, H., Tegner, Y. & Blennow, K. Serum neurofilament light as a biomarker for
mild traumatic brain injury in contact sports. Neurology 88, 1788–1794 (2017).
283. Kalm, M. et al. Serum concentrations of the axonal injury marker neurofilament light protein are
not influenced by blood-brain barrier permeability. Brain research 1668, 12–19 (2017).
284. Ehrlich, S. et al. S100B in underweight and weight-recovered patients with anorexia nervosa.
Psychoneuroendocrinology 33, 782–788 (2008).
285. Ehrlich, S. et al. Glial and neuronal damage markers in patients with anorexia nervosa. Journal of
neural transmission (Vienna, Austria : 1996) 115, 921–927 (2008).
286. Yang, L. L. et al. Enteric short-chain fatty acids promote proliferation of human neural progenitor
cells. Journal of Neurochemistry (2019) doi:10.1111/jnc.14928.
287. Open Science Collaboration. Estimating the reproducibility of psychological science. Science 349,
aac4716–aac4716 (2015).
288. Baker, M. 1,500 scientists lift the lid on reproducibility. Nature News Feature (2016).
289. Amrhein, V., Greenland, S. & McShane, B. Scientists rise up against statistical significance. (2019).
290. Blacker, C. J. et al. EAAT2 as a research target in bipolar disorder and unipolar depression: A
systematic review. Molecular Neuropsychiatry 1–16 (2019) doi:10.1159/000501885.
291. Woolley, A. W., Chabris, C. F., Pentland, A., Hashmi, N. & Malone, T. W. Evidence for a collective
intelligence factor in the performance of human groups. Science 330, 686–688 (2010).
292. Credé, M. & Howardson, G. The structure of group task performanceA second look at “collective
intelligence”: Comment on woolley et al. (2010). Journal of Applied Psychology 102, 1483–1492 (2017).
89
